deferasirox profile

Deferasirox: A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

deferasirox : A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	214348
CHEMBL ID	550348
CHEBI ID	49005
SCHEMBL ID	61756
SCHEMBL ID	62042
SCHEMBL ID	1071867
MeSH ID	M0490722

Synonym
HY-17359
icl-670a
icl-670
deferasirox
cgp-72670
exjade
deferasirox (jan/usan/inn)
D03669
201530-41-8
exjade (tn)
jadenu (tn)
NCGC00181754-01
4-(3,5-bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid
deferasiroxum
icl 670
CHEBI:49005 ,
icl 670a
4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]benzoic acid
DB01609
deferasiroxum [inn-latin]
4-(3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl)benzoic acid
icl670
icl670a
benzoic acid, 4-(3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl)-
bdbm50088376
osveral
CHEMBL550348
FT-0665569
4-[(3z,5e)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid
cas-201530-41-8
dtxsid1048596 ,
dtxcid1028522
tox21_112926
A814288
4-[3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid
BCP9000594
4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid
jadenu
unii-v8g4mof2v9
v8g4mof2v9 ,
jadenu sprinkle
hsdb 7844
deferasirox [usan:inn:jan]
smr002544689
MLS003915634
FT-0601564
deferasirox [mart.]
deferasirox [mi]
deferasirox [jan]
deferasirox [vandf]
deferasirox [inn]
deferasirox [usan]
deferasirox [orange book]
deferasirox [ema epar]
deferasirox [usp-rs]
deferasirox [ep monograph]
deferasirox [who-dd]
deferasirox [hsdb]
CS-0901
S1712
AKOS015902587
AKOS015855839
SCHEMBL61756
SCHEMBL62042
BOFQWVMAQOTZIW-UHFFFAOYSA-N
4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid
MLS006010080
tox21_112926_1
NCGC00263572-01
deferasirox, icl670
KE-0220
SCHEMBL1071867
4-((3e,5e)-3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoic acid
1044764-54-6
F0001-2380
4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]benzoic acid; cgp-72670; icl-670; icl-670a
AB01565800_02
mfcd09951804
AKOS025312553
benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-
AC-8972
sr-01000931971
SR-01000931971-2
4-[(3z,5e)-3,5-bis(6-oxo-2,4-cyclohexadien-1-ylidene)-1,2,4-triazolidin-1-yl]benzoic acid, aldrichcpr
HMS3655A04
mfcd09751362
J-013060
4-[bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]benzoic acid
SW219752-1
BCP05341
Q5251502
deferasirox (exjade)
EX-A4091
SB18926
CCG-268337
4-(3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoic acid
deferasirox 100 microg/ml in acetonitrile
JBL ,
EN300-26907573
4-[(3z,5e)-3,5-bis(6-oxocyclohexa-2,4-dien-1ylidene)-1,2,4-triazolidin-1-yl] benzoic acid
4-(3,5-bis(6-oxocyclohexa-2,4-dien-1-ylidene)-1,2,4-triazolidin-1-yl)benzoicacid
D5905
deferasirox (ep monograph)
deferasirox (mart.)
deferasirox oral
deferasorox
deferasiroxum (inn-latin)
deferasirox (usp-rs)
v03ac03
deferasirox oral granules
4-(3,5-bis-(hydroxy-phenyl)-1,2,4-triazol-1-yl)-benzoic acid
Z3041510169
4-{3,5-bis[(1e)-6-oxocyclohexa-2,4-dien-1-ylidene]-1,2,4-triazolidin-1-yl}benzoic acid
PD087125

Excerpt	Reference	Relevance
"Deferasirox (DFX) is an iron-chelating agent effective in treating various kinds of cancers, which inhibits iron metabolism in cancer cells. "	( Thermosensitive TMPO-oxidized lignocellulose/cationic agarose hydrogel loaded with deferasirox nanoparticles for photothermal therapy in melanoma. Mirian, M; Rostami, M; Varshosaz, J; Veisi, H, 2023)	2.58
"Deferasirox is an active iron chelator, used in the treatment of iron overload such as hemochromatosis. "	( Aguilar Hinojosa, NK; Figueroa Saavedra, EI, 2023)	2.35
"Deferasirox is an oral iron chelator with established dose-dependent efficacy for the treatment of iron overload secondary to transfusion. "	( The challenges of handling deferasirox in sickle cell disease patients older than 40 years. Benites, BD; Costa, FF; Gilli, SCO; Olalla Saad, ST; Ribeiro, LB; Soares, EA, 2019)	2.25
"Deferasirox is a once-daily oral iron-chelation agent approved by the US Food and Drug Administration in November 2005. "	( Evaluation of Efficacy, Safety, and Satisfaction Taking Deferasirox Twice Daily Versus Once Daily in Patients With Transfusion-Dependent Thalassemia. Ansari, S; Azarkeivan, A; Bahoush, G; Bazrafshan, A; Haghpanah, S; Jangjou, A; Karimi, M; Shahsavani, A, 2020)	2.25
"Deferasirox (DFX) is an iron chelator approved for the treatment of iron overload diseases. "	( Deferasirox protects against hydrogen peroxide-induced cell apoptosis by inhibiting ubiquitination and degradation of p21 Cao, P; Chang, Y; Duan, X; Fan, Y; Hasem, H; Hou, J; Kuang, Y; Miao, J; Pan, S; Tan, K; Xu, M; Zhou, N, 2020)	3.44
"Deferasirox (DFX) is an oral iron-chelating agent and classified into class II of the Biopharmaceutics Classification System. "	( Solid Dispersion Pellets: An Efficient Pharmaceutical Approach to Enrich the Solubility and Dissolution Rate of Deferasirox. Abbaspour, M; Ebrahimnejad, P; Farmoudeh, A; Nokhodchi, A; Rezaeiroshan, A, 2020)	2.21
"Deferasirox (DFR) is a trivalent iron chelator, which was approved to treat iron overload syndrome after transfusion."	( Deferasirox, a trivalent iron chelator, ameliorates neuronal damage in hemorrhagic stroke models. Hara, H; Imai, T; Matsubara, H; Nakamura, S; Ohba, T; Shimazawa, M; Sugiyama, T; Tsuji, S, 2021)	2.79
"Deferasirox is an effective iron chelator when started at an optimum time and with optimum dose. "	( Effectiveness of Deferasirox in Pediatric Thalassemia Patients: Experience from a Tertiary Care Hospital of Odisha. Debta, N; Jena, RK; Panigrahi, A; Panigrahi, M; Swain, TR, )	1.91
"Deferasirox is an oral iron chelator used to reduce iron levels in iron-overloaded patients with transfusion-dependent anemia or non-transfusion-dependent thalassemia. "	( Effect of Genetic Polymorphisms on the Pharmacokinetics of Deferasirox in Healthy Chinese Subjects and an Artificial Neural Networks Model for Pharmacokinetic Prediction. Chen, J; Hu, Y; Jiang, B; Lou, H; Ruan, Z; Shao, R; Xu, Y; Yang, D, 2020)	2.24
"Deferasirox is an oral iron chelator that has been on the market since 2005 and has been a suitable replacement for injectable chelators. "	( Sensitive determination of deferasirox in blood of patients with thalassemia using dispersive liquid-liquid microextraction based on solidification of floating organic drop followed by HPLC-UV. Akramipour, R; Fattahi, N; Golpayegani, MR, 2021)	2.36
"Deferasirox, ExJade, is an FDA-approved iron chelator used for the treatment of iron overload. "	( Deferasirox (ExJade): An FDA-Approved AIEgen Platform with Unique Photophysical Properties. Brewster, JT; Han, HH; He, XP; Hu, XL; Lynch, VM; Mangel, DN; Sedgwick, AC; Sessler, JL; Shang, Y; Snelson, DW; Steinbrueck, A; Tian, H; Yan, KC, 2021)	3.51
"Deferasirox is an oral chelator approved for iron overload, which has a potential side effect of renal Fanconi syndrome, with proximal tubular dysfunction and tubular acidosis. "	( Deferasirox-associated Fanconi syndrome in adult patients with transfusional iron overload. Geara, A; Sayani, F; Yui, JC, 2021)	3.51
"As deferasirox (DFX) is an approved Fe chelator drug, its inability to cross blood brain barrier (BBB) remains a definite obstacle against its use as Fe chelator in the brain."	( Destructive effect of iron overload in brain tissue of albino rats: Ameliorative role of silver immobilized organo-modified casein nanocomposite as co-treating agent with Deferasirox. Adel, RM; Amer, AS; Darwish, AS; Lotfy, RA, 2021)	1.33
"Deferasirox is an orally active, lipophilic iron chelating drug used on thousands of patients worldwide for the treatment of transfusional iron overload. "	( Antioxidant Activity of Deferasirox and Its Metal Complexes in Model Systems of Oxidative Damage: Comparison with Deferiprone. Kichigina, LA; Kontoghiorghes, GJ; Polyakov, NE; Selyutina, OY; Timoshnikov, VA, 2021)	2.37
"Deferasirox is an iron chelator agent used in the treatment of diseases with iron overload, such as thalassemia and myelodysplastic syndrome. "	( Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome. Belli, AA; Dere, Y; Karakus, V; Polat, AK, 2017)	3.34
"Deferasirox is an oral iron-chelating agent having possible antileukemia and immune modulatory effects. "	( Improved survival outcomes and restoration of graft-vs-leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia. Cho, BS; Cho, SG; Eom, KS; Hahn, AR; Jeon, YW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Lee, TH; Min, CK; Min, WS; Park, SS; Yoon, JH, 2019)	2.19
"Deferasirox is a potent NF-kB inhibitor, tested in vivo and on acute myeloid leukemia and MDS cell lines, and this effect may explain in part the phenomenon of hematological improvements reported in case reports and in different clinical trials."	( Efficacy and safety of deferasirox in myelodysplastic syndromes. Alimena, G; Breccia, M, 2013)	1.42
"Deferasirox is a once-daily, oral iron chelator that was developed out of a need for a long-acting, conveniently-administered chelator for patients with transfusional hemosiderosis. "	( The palatability and tolerability of deferasirox taken with different beverages or foods. Chirnomas, D; Esposito, J; Giardina, PJ; Goldberg, SL; Paley, C; Vichinsky, E, 2013)	2.11
"Deferasirox is a new treatment of iron overload that is administered orally once-a-day, resulting in better acceptance in patients. "	( Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature. Bianchetti, MG; Brazzola, P; Dell'Orto, VG, 2013)	2.07
"Deferasirox (Exjade(®)) is a once-daily orally administered iron chelator which has been approved for use in the treatment of transfusional-dependent chronic iron overload since 2005. "	( Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia. Plosker, GL; Shirley, M, 2014)	3.29
"Deferasirox (DFX) is an effective and well-tolerated oral iron chelator elevating the adherence to iron chelating therapy among patients with iron overload. "	( Safety of deferasirox: a retrospective cohort study on the risks of gastrointestinal, liver and renal events. Chou, HC; Hsiao, FY; Huang, WF; Tsai, YW, 2014)	2.25
"Deferasirox is an oral iron chelator effective for reduction of body iron in iron-overloaded patients with transfusion-dependent anemias and non-transfusion-dependent thalassemia, with a well-established safety profile."	( Clinical pharmacology of deferasirox. Tanaka, C, 2014)	1.43
"Deferasirox (DFX) is an oral iron chelator with established efficacy and safety. "	( A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients. Cappellini, MD; Cassinerio, E; Consonni, D; Giuditta, M; Orofino, N; Pedrotti, P; Poggiali, E; Roghi, A; Zanaboni, L, 2015)	2.17
"Deferasirox (DFX) is an orally administered iron chelator approved for use in patients with transfusion-dependent iron overload due to myelodysplastic syndromes (MDS). "	( Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata. Aloe Spiriti, MA; Breccia, M; Buccisano, F; Criscuolo, M; D'Addosio, A; Fenu, S; Fragasso, A; Latagliata, R; Maurillo, L; Musto, P; Niscola, P; Piccioni, AL; Refrigeri, M; Tatarelli, C; Trapè, G; Venditti, A; Voso, MT, 2015)	3.3
"Deferasirox is a new oral iron chelating agent with several cases reporting renal adverse events in recent years. "	( Transfusion-dependent thalassaemic patients with renal Fanconi syndrome due to deferasirox use. Chuang, GT; Lu, MY; Tsai, IJ; Tsau, YK, 2015)	2.09
"Deferasirox is a novel once-daily, oral iron chelator. "	( The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan. Chang, HH; Jou, ST; Lin, DT; Lin, KH; Lu, MY; Peng, SS; Yang, YL, 2015)	2.12
"Deferasirox is an oral iron chelator used widely in the treatment of thalassemia major and other transfusion-dependent hemoglobinopathies. "	( Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria. Bowden, DK; Doery, JC; Fuller, PJ; Gillespie, MT; Kerr, PG; Larmour, I; Milat, F; Polkinghorne, K; Wong, P, 2016)	3.32
"Deferasirox is an oral iron chelator."	( The potential of deferasirox as a novel therapeutic modality in gastric cancer. Choi, JH; Kim, JS; Lee, YY; Park, BB; Uhm, J; Won, YW, 2016)	1.5
"Deferasirox is a standard treatment for chronic transfusional iron overload. "	( Proximal muscular atrophy and weakness: An unusual adverse effect of deferasirox iron chelation therapy. Albert, MH; Blaschek, A; Gerstl, L; Huetker, S; Müller-Felber, W; Teusch, V; Vill, K, )	1.81
"Deferasirox is an oral iron chelator used to treat patients with transfusion-related iron overload. "	( Fanconi Syndrome Secondary to Deferasirox in Diamond-Blackfan Anemia: Case Series and Recommendations for Early Diagnosis. Arora, S; Athale, UH; Bhatt, MD; Kirby-Allen, M; Papneja, K; Wiernikowski, JT, 2016)	2.17
"Deferasirox is a once-daily orally active tridentate selective iron chelator which pharmacokinetic disposition could influence treatment efficacy and toxicity."	( Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients. Allegra, S; Cusato, J; D'Avolio, A; De Francia, S; Massano, D; Piga, A; Pirro, E, 2017)	2.62
"Deferasirox is an oral chelator."	( Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox. Avazpour, A; Badie, A; Haghpanah, S; Karimi, M; Toosi, F, 2017)	1.39
"Deferasirox is an oral active iron chelating agent."	( The questioning for routine monthly monitoring of proteinuria in patients with β-thalassemia on deferasirox chelation. Bayhan, T; Gümrük, F; Karabulut, E; Küçüker, H; Tutal, AD; Ünal, Ş; Ünlü, O, 2017)	1.39
"Deferasirox is an oral iron chelator used to treat blood transfusion-related iron overload."	( Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells. Carrasco, S; Egido, J; Fontecha-Barriuso, M; Gallegos-Villalobos, A; Lopez-Hernandez, FJ; Martin-Sanchez, D; Ortiz, A; Ruiz-Ortega, M; Sanchez-Niño, MD; Sanz, AB, 2017)	2.62
"Deferasirox is a novel iron chelator formulated as tablets for dispersion (suspension) for once-a-day oral administration. "	( Absolute oral bioavailability and disposition of deferasirox in healthy human subjects. Balez, S; Belleli, R; Robeva, A; Séchaud, R, 2008)	2.04
"Deferasirox is a new iron chelator approved recently for chelation therapy in iron-overloaded patients. "	( Hypocalcemia in a dialysis patient treated with deferasirox for iron overload. Brewster, UC; McPhedran, P; Yusuf, B, 2008)	2.04
"Deferasirox is a new oral iron chelator used to treat transfusional iron overload. "	( Acute interstitial nephritis due to deferasirox: a case report. Brosnahan, G; Gokden, N; Swaminathan, S, 2008)	2.06
"Deferasirox is an oral iron chelator, with a long half-life, that can be given once daily, because it provides a 24-hour chelation. "	( Long-term efficacy and safety of deferasirox. Cappellini, MD, 2008)	2.07
"Deferasirox is an innovative iron-chelating treatment. "	( Fanconi syndrome due to deferasirox. Delarue, R; Fakhouri, F; Le Quintrec, M; Rafat, C; Ribeil, JA, 2009)	2.1
"Deferasirox is a novel, orally active agent that provides 24-h chelation with a once-daily dose."	( Oral iron chelators. Cappellini, MD; Pattoneri, P, 2009)	1.07
"Deferasirox is a novel, once daily oral iron chelator that was recently approved for the treatment of transfusional iron overload."	( Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil. Al-Rousan, RM; Blough, ER; Gutta, AK; Kakarla, SK; Laurino, JP; Paturi, S; Walker, EM, 2009)	2.52
"Deferasirox is a once-daily, orally administered, tridentate iron chelator that is indicated in the treatment of iron overload resulting from regular packed red blood cell transfusions in patients with transfusion-dependent anemias, such as beta-thalassemia, sickle cell disease, myelodysplastic syndrome and other rare anemias. "	( Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes. Imran, F; Phatak, P, 2009)	2.09
"Deferasirox (DFX) is a daily oral iron chelator approved in the United States for transfusional iron overload."	( Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy. Alvarez, O; Lewis, N; Lopez-Mitnik, G; Paley, C; Pow Sang, CD; Robinson, N; Rodriguez-Cortes, H, 2009)	1.44
"Deferasirox is a once-daily oral iron chelator with established dose-dependent efficacy in both adult and pediatric patients with transfusional iron overload. "	( Deferasirox (Exjade) for the treatment of iron overload. Cappellini, MD; Taher, A, 2009)	3.24
"Deferasirox (DFX) is a newly developed oral iron chelator that enables effective chelation with once daily administration. "	( Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome. HATANO, K; MATSUYAMA, T; MORI, M; MUROI, K; NAGAI, T; OKABE, H; OMORI, T; OZAWA, K; QZAKI, K; SUZUKI, T; TOSHIMA, M; UEDA, M; UEHARA, E, 2009)	2.05
"Deferasirox (ICL670) is a novel once-daily, orally administered iron chelator to treat chronic iron overload in patients with transfusion-dependent anemias. "	( Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Bruin, GJ; Glaenzel, U; Hazell, K; Porter, JB; Sechaud, R; Waldmeier, F; Warrington, S, 2010)	2.06
"Deferasirox (Exjade) is a once-daily, oral iron chelator approved for the treatment of transfusional iron overload. "	( Cystatin C levels in patients with beta-thalassemia during deferasirox treatment. Delaporta, P; Goussetis, E; Hantzi, E; Kattamis, A; Ladis, V; Margeli, A; Papassotiriou, I; Sergounioti, A, 2010)	2.05
"Deferasirox is an oral alternative to the well studied but inconvenient deferroxamine therapy."	( A method to measure deferasirox in plasma using HPLC coupled with MS/MS detection and its potential application. Bouchet, S; Chauzit, E; Mahon, FX; Micheau, M; Molimard, M; Moore, N; Titier, K, 2010)	1.41
"Deferasirox is an orally administered iron chelator which is effective on iron overloaded patients with transfusion-dependent anemia."	( Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia. Christoulas, D; Dimopoulou, M; Douskou, M; Mpoutou, E; Plata, E; Sioni, A; Terpos, E; Voskaridou, E, 2011)	2.53
"Deferasirox is a recently approved oral iron chelator for treatment of patients with transfusion-related iron overload. "	( Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox. Barzilai-Birenbaum, S; Krause, I; Pazgal, I; Stark, P; Tamary, H; Yacobovich, J; Yaniv, I, 2010)	2.03
"Deferasirox is an oral iron-chelating agent taken once-daily by patients with transfusion-dependent iron overload. "	( Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia. Chang, HH; Chang, TT; Chiou, SS; Jou, ST; Liao, YM; Lin, DT; Lin, KH; Lin, PC; Lu, MY; Yang, YL, 2011)	2.07
"Deferasirox (DFRA) is a new approved oral iron chelator. "	( Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months. Cheng, CH; Lo, FS; Wei, HY; Yang, CP, 2011)	2.05
"Deferasirox is a new oral iron chelator. "	( [Deferasirox--a new oral iron chelator--review]. Chen, BA; Gao, C; Wang, T, 2010)	2.71
"Deferasirox is a relatively new oral iron chelator and experience of its use in children is limited."	( Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major. Chandra, J; Chaudhary, H; Dutta, AK; Pemde, H; Singh, V, 2011)	1.4
"Deferasirox is a new oral chelator with high iron-binding potency and selectivity."	( Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil. Al-Rousan, RM; Blough, ER; Katta, A; Laurino, J; Rice, KM; Triest, WE; Walker, EM; Wu, M, 2011)	2.53
"Deferasirox (DFX) is an orally administered iron chelator which has been highly efficient in the treatment of secondary iron overload."	( Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox. Almeida, A; Angelucci, E; Beris, P; Guerci-Bresler, A; Hofmann, WK; Macwhannell, A; Muus, P; Nolte, F; Porter, J; Schumann, C; Selleslag, D; Sliwa, T; Xicoy, B, 2011)	1.29
"Deferasirox (DFX) is an oral iron chelator that is used worldwide for the treatment of iron overload. "	( Interference of deferasirox with assays for serum iron and serum unsaturated iron binding capacity during iron chelating therapy. Fujiya, M; Ikuta, K; Ito, S; Kohgo, Y; Sasaki, K; Tanaka, H; Torimoto, Y, 2011)	2.16
"Deferasirox (Exjade®) is an oral tridentate iron chelator used for reducing iron overload."	( Deferasirox: pharmacokinetics and clinical experience. Campus, S; Galanello, R; Origa, R, 2012)	2.54
"Deferasirox (DFX) is a relatively new iron chelator approved by the US Food and Drug Administration for treatment of children >2 years of age. "	( Efficacy of deferasirox in North Indian β-thalassemia major patients: a preliminary report. Bansal, D; Marwaha, RK; Panigrahi, I; Vaidya, PC, 2012)	2.2
"Deferasirox is an oral, easily applicable, and effective iron chelator; baseline hepatotoxicity and nephrotoxicity may increase the development of toxic side effects in children with FAA."	( Deferasirox therapy in children with Fanconi aplastic anemia. Azik, FM; Culha, V; Kara, A; Karakurt, N; Ozkasap, S; Tavil, B; Tunç, B; Yarali, N, 2012)	2.54
"Deferasirox (DFX) is an oral iron chelator with an established dose-dependent efficacy in transfusion-related iron overload. "	( Deferasirox-induced renal impairment in children: an increasing concern for pediatricians. Cochat, P; Dubourg, L; Hadj-Aïssa, A; Laurain, C; Pondarré, C; Ranchin, B; Sigaudo-Roussel, D, 2012)	3.26
"Deferasirox is a new oral iron chelator used to treat transfusional iron overload. "	( First report of drug-induced esophagitis by deferasirox. Araki, H; Hara, T; Moriwaki, H; Oyama, M; Tsurumi, H; Yoshikawa, T, 2012)	2.08
"Deferasirox is a newer chelation therapy that is taken orally once daily."	( Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective. Chandiwana, D; Karnon, J; Tolley, K; Vieira, J, 2012)	1.38
"Deferasirox is an iron chelating agent for the treatment of transfusional iron over load in patients with chronic anemia. "	( Dried blood spot analysis of an iron chelator--deferasirox and its potential application to therapeutic drug monitoring. Ajjala, DR; Aleti, R; Kandikere, V; Nirogi, R; Srikakolapu, S; Vurimindi, H, 2012)	2.08
"Deferasirox is an orally effective iron (Fe) chelator currently used for the treatment of iron-overload disease and has been implemented as an alternative to the gold standard chelator, desferrioxamine (DFO). "	( The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Ford, SJ; Jansson, PJ; Kalinowski, DS; Kovacevic, Z; Lovejoy, DB; Lui, GY; Obeidy, P; Richardson, DR; Sharp, DM; Tselepis, C, 2013)	2.16
"Deferasirox (DFRA) is a novel oral chelator agent for treatment of iron overload. "	( Safety and efficacy of 4 years of deferasirox treatment for sickle cell disease patients. Bekiari, E; Mainou, M; Tsapas, A; Vetsiou, E; Vlachaki, E, 2013)	2.11
"Deferasirox (DFX) is a novel iron chelator that has been shown to have similar efficacy and safety compared with deferoxamine (DFO) in patients with β-thalassemia. "	( Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients. Javanbakht, M; Karimi, M; Keshtkaran, A; Mashayekhi, A; Nuri, B; Salavati, S, 2013)	2.12
"Deferasirox (ICL670) is a once-daily oral iron chelator developed for the treatment of chronic iron overload from blood transfusions. "	( A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Agaoglu, L; Alberti, D; Athanassiou-Metaxa, M; Aydinok, Y; Bejaoui, M; Cappellini, MD; Capra, M; Coates, T; Cohen, A; Drelichman, G; Fattoum, S; Galanello, R; Giardina, P; Janka-Schaub, G; Kattamis, A; Kilinc, Y; Kourakli-Symeonidis, A; Magnano, C; Marks, P; Olivieri, N; Opitz, H; Perrotta, S; Piga, A; Porter, J; Ressayre-Djaffer, C; Thuret, I; Verissimo, M; Vermylen, C, 2006)	2.1
"Deferasirox is an orally active iron chelator. "	( Deferasirox--an oral agent for chronic iron overload. Hagemann, TM; Vanorden, HE, 2006)	3.22
"Deferasirox (ICL670) is a novel once-daily oral iron chelator developed for the treatment of chronic iron overload from blood transfusions. "	( Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Alberti, D; Belleli, R; Bertrand, Y; Bordone, E; Forni, GL; Foschini, ML; Galanello, R; Hewson, N; Lavagetto, A; Leoni, G; Longo, F; Maseruka, H; Piga, A; Sechaud, R; Zappu, A, 2006)	2.06
"Deferasirox is a once-daily, oral iron chelator developed for treating transfusional iron overload. "	( A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Alberti, D; Bernaudin, F; Coates, T; Eckman, J; Files, B; Fischer, R; Forni, GL; Fung, E; Hassell, K; Holland, J; Kelly, P; Lane, P; Marks, P; Mueller, BU; Okpala, I; Onyekwere, O; Porter, J; Ressayre-Djaffer, C; Swerdlow, P; Vichinsky, E; Wilson, F, 2007)	2.08
"Deferasirox is an oral tridentate chelator that mobilizes iron stores by binding selectively to the ferric form of iron."	( Deferasirox. Stumpf, JL, 2007)	2.5
"Deferasirox is a recently approved once-daily oral iron chelator that has been shown to reduce liver iron concentrations and serum ferritin levels to a similar extent as infusional deferoxamine."	( Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Baladi, JF; Coates, TD; Delea, TE; Phatak, PD; Sofrygin, O; Thomas, SK, 2007)	2.02
"Deferasirox (DSX) is a recently developed oral chelator which shows good efficacy and tolerability in patients with transfusional hemosiderosis due to various underlying disorders."	( Recent developments in iron chelation therapy. Cario, H; Janka-Schaub, G; Janssen, G; Jarisch, A; Kohne, E; Strauss, G, )	0.85
"Deferasirox is an orally administered iron chelator that has been approved for use in the United States, Switzerland, and other countries."	( Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Abetz, L; Abish, S; Agaoglu, L; Baladi, JF; Bejaoui, M; Cappellini, MD; Cario, H; Coates, T; Ferster, A; Girot, R; Jeng, M; Lai, ME; Loggetto, S; Mangiagli, A; Opitz, H; Porter, J; Ressayre-Djaffer, C; Rofail, D; Strauss, G; Vichinsky, E; Watman, N; Zoumbos, N, 2007)	1.29
"Deferasirox is a new orally effective iron chelator which has been shown to be non-inferior to deferoxamine in clinical trials."	( Current status of iron overload and chelation with deferasirox. Choudhry, VP; Naithani, R, 2007)	1.31
"Deferasirox is a new tridentate oral iron chelator developed by computer remodeling recently approved by FDA for children above 2 years. "	( Deferasirox: the new oral iron chelator. Dubey, AP; Parakh, A; Sudha, S, 2007)	3.23
"Deferasirox (Exjade) is an oral, once-daily iron chelator widely approved for the treatment of transfusional chronic iron overload. "	( Deferasirox : a review of its use in the management of transfusional chronic iron overload. Keam, SJ; Keating, GM; Yang, LP, 2007)	3.23
"Deferasirox is an oral iron-chelating agent with favorable pharmacokinetics, including a long half-life allowing continuous 24-hour chelation with once-daily dosing."	( Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. Goldberg, SL, 2007)	1.06
"Deferasirox is a new once-daily oral agent for iron overload that was approved by the US Food and Drug Administration in November 2005."	( Deferasirox for transfusion-related iron overload: a clinical review. Lindsey, WT; Olin, BR, 2007)	2.5

Excerpt	Reference	Relevance
"Deferasirox has an acceptable tolerability profile, with the most common adverse events reported in the THALASSA trial being related to mild to moderate gastrointestinal disorders."	( Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia. Plosker, GL; Shirley, M, 2014)	2.57
"Deferasirox monotherapy has a good safety profile and effectively chelates total body iron. "	( Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia. Ahmed, J; Jankharia, B; Krishnan, P; Merchant, R, 2012)	2.13
"Deferasirox has a manageable safety profile with favorable patient satisfaction reports."	( Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. Goldberg, SL, 2007)	1.06
"Deferasirox has been reported to inhibit NF-κB activity and suppress phosphorylation of the MAPK pathway."	( Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing. Choi, CW; Jeon, MJ; Kim, DS; Yu, ES, 2023)	1.63
"Deferasirox has shown antioxidant activity in all three model systems, causing substantial reduction in the rate of oxidation and oxidative damage."	( Antioxidant Activity of Deferasirox and Its Metal Complexes in Model Systems of Oxidative Damage: Comparison with Deferiprone. Kichigina, LA; Kontoghiorghes, GJ; Polyakov, NE; Selyutina, OY; Timoshnikov, VA, 2021)	1.65
"Deferasirox has nephrotoxic effects in the context of chronic therapy. "	( A case of Fanconi syndrome due to a deferasirox overdose and a trial of plasmapheresis. Powell, JL; Shah, L; Zaritsky, JJ, 2017)	2.17
"Deferasirox has long-term efficacy and safety in children with TDT and SCA, although higher doses (≥30 mg/kg/d) may be required to achieve iron balance."	( Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM). Akın, M; Akkaynak, D; Antmen, B; Apak, H; Aral, YZ; Aydogan, G; Ayhan, AC; Biner, B; Çalışkan, Ü; Eren, TG; Ertem, M; Gümrük, F; İrken, G; Işık Balcı, Y; Karakaş, Z; Karasu, G; Kazancı, EG; Koç, A; Koçak, Ü; Küpesiz, OA; Kurtoğlu, E; Meral Güneş, A; Oktay, G; Oymak, Y; Patıroğlu, T; Salcioglu, Z; Şaşmaz, İ; Söker, M; Timur, Ç; Tunç, B; Türkkan, E; Ünal, S; Uygun, V; Vergin, C; Yeşilipek, MA; Yıldırmak, Y, 2019)	3.4
"Deferasirox (DFX) has recently been used to treat thalassemia with iron overload; however, its long-term effectiveness and safety await multi-year studies. "	( Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis. Chen, G; Dou, H; Qin, Y; Zhao, Y, 2019)	2.25
"Oral deferasirox has been licensed for use in children aged over six years who receive frequent blood transfusions and in children aged two to five years who receive infrequent blood transfusions. In the absence of randomised controlled trials with long-term follow up, there is no compelling evidence to change this conclusion.Worsening iron deposition in the myocardium in patients receiving desferrioxamine alone would suggest a change of therapy by intensification of desferrioxamine treatment or the use of desferrioxamine and deferiprone combination therapy.Adverse events are increased in patients treated with deferiprone compared with desferrioxamine and in patients treated with combined deferiprone and desferrioxamine compared with desferrioxamine alone."	( Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ, 2013)	0.84
"Deferasirox has an acceptable tolerability profile, with the most common adverse events reported in the THALASSA trial being related to mild to moderate gastrointestinal disorders."	( Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia. Plosker, GL; Shirley, M, 2014)	2.57
"Deferasirox (DFX) has been licensed for iron chelation in patients with sickle cell disease (SCD), but there is limited data on its long-term efficacy and safety in children. "	( Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network. Gadong, N; Hemmaway, C; Kaya, B; Newell, H; Simmons, A; Telfer, P; Tsouana, E; Whitmarsh, S, 2015)	3.3
"Deferasirox has been identified to cause fatal gastrointestinal hemorrhages, renal tubulopathy, hepatic and renal failure, alopecia and anaphylactic reactions in addition to previously reported fatal or serious toxic side effects such as agranulocytosis, renal and hepatic toxicity, skin rash and gastric intolerance."	( Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Kontoghiorghes, GJ, 2010)	1.37
"Deferasirox monotherapy has a good safety profile and effectively chelates total body iron. "	( Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia. Ahmed, J; Jankharia, B; Krishnan, P; Merchant, R, 2012)	2.13
"Deferasirox has been studied in patients older than 2 years and appears to be safe, with the most common adverse effects reported being mild, transient nausea, gastrointestinal disturbances, and rash."	( Deferasirox--an oral agent for chronic iron overload. Hagemann, TM; Vanorden, HE, 2006)	2.5
"Deferasirox has been studied in >700 adult and pediatric patients who had transfusion-related iron overload and underlying thalassemia, sickle cell anemia, myelodysplastic syndrome, Diamond-Blackfan syndrome, or another rare anemia."	( Deferasirox. Stumpf, JL, 2007)	2.5
"Deferasirox has a manageable safety profile with favorable patient satisfaction reports."	( Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. Goldberg, SL, 2007)	1.06
"Deferasirox has exhibited high potency and a clinically manageable safety profile in preclinical models and in an extensive clinical program."	( Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. Alberti, D; Balez, S; Belleli, R; Cappellini, MD; Dutreix, C; Ford, JM; Forni, GL; Galanello, R; Origa, R; Piga, A; Rivière, GJ; Séchaud, R; Zappu, A, 2008)	1.31
"Deferasirox (ICL670) has been shown to have rapid accessibility to intracellular labile iron. "	( Effect of deferasirox (ICL670) on arterial function in patients with beta-thalassaemia major. Chan, GC; Cheung, YF; Ha, SY, 2008)	2.19

Excerpt	Reference	Relevance
"Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels."	( Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Andes, D; Anglim, A; Bonilla, H; Ibrahim, AS; Mathisen, GE; Perez, M; Spellberg, B; Walsh, TJ, 2009)	1.35
"Deferasirox treatment reduced the level of pro inflammatory cytokines (IL-1β, IL-6, TNF-α and INF-γ)."	( Deferasirox alleviates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and improving intestinal microbiota. Chunyu, W; Gao, X; Liu, S; Peng, M; Ran, L; Sun, L; Wan, J; Wang, Y; Wu, Y; Yang, K; Yang, Y; Yin, M, 2023)	3.07
"Deferasirox is a new treatment of iron overload that is administered orally once-a-day, resulting in better acceptance in patients. "	( Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature. Bianchetti, MG; Brazzola, P; Dell'Orto, VG, 2013)	2.07
"Deferasirox treatment may be clinically beneficial both by reducing iron overload and by improving hematopoiesis in patients with PRCA."	( Deferasirox treatment improved hematopoiesis and led to complete remission in a patient with pure red cell aplasia. Ando, K; Kojima, M; Machida, S; Miyamoto, M; Moriuchi, M; Ohbayashi, Y; Sato, A, 2013)	2.55
"Deferasirox is a standard treatment for chronic transfusional iron overload. "	( Proximal muscular atrophy and weakness: An unusual adverse effect of deferasirox iron chelation therapy. Albert, MH; Blaschek, A; Gerstl, L; Huetker, S; Müller-Felber, W; Teusch, V; Vill, K, )	1.81
"Deferasirox treatment or phlebotomy reduces iron burden in pediatric patients with β- thalassemia major post-HSCT, with a manageable safety profile."	( One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. Abbas, HA; Cappellini, MD; Inati, A; Kahale, M; Koussa, S; Musallam, KM; Nasr, TA; Porter, JB; Sbeiti, N; Taher, AT, 2017)	2.13
"Deferasirox treatment was taken post iron loading and was given at 100 mg/kg/day p.o for 1 or 3 months."	( Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil. Al-Rousan, RM; Blough, ER; Gutta, AK; Kakarla, SK; Laurino, JP; Paturi, S; Walker, EM, 2009)	2.52
"Deferasirox chelation treatment regimen was well tolerated and adherence to the regimen was good."	( Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI. Borsellino, Z; Cuccia, L; Gagliardotto, F; Marocco, MR; Ruffo, GB; Tarantino, R, 2010)	1.36
"Deferasirox treatment decreased cardiac iron levels by 37% (P < 0.05), and this was associated with decreases in the number of TUNEL-positive cells."	( Deferasirox decreases age-associated iron accumulation in the aging F344XBN rat heart and liver. Arvapalli, RK; Blough, ER; Gadde, MK; Kakarla, SK; Katta, A; Laurino, JP; Paturi, S; Rice, KM; Walker, EM; Wehner, P; Wu, M, 2010)	2.52
"Deferasirox treatment also was associated with reduced hepatic protein oxidation, superoxide abundance, and cell death."	( Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil. Al-Rousan, RM; Blough, ER; Katta, A; Laurino, J; Rice, KM; Triest, WE; Walker, EM; Wu, M, 2011)	2.53
"Deferasirox treatment (25 mg/kg/day) was initiated when serum ferritin levels increased to more than 1,000 ng/ml during induction chemotherapy."	( Iron chelation treatment with deferasirox prior to high-dose chemotherapy and autologous stem cell transplantation may reduce the risk of hepatic veno-occlusive disease in children with high-risk solid tumors. Cho, EJ; Chueh, HW; Kim, JY; Koo, HH; Lee, SH; Sung, KW; Yoo, KH, 2012)	1.39
"Deferasirox treatment was completed as scheduled in 11 (61.1%) of them without dose reduction or discontinuation."	( Iron chelation treatment with deferasirox prior to high-dose chemotherapy and autologous stem cell transplantation may reduce the risk of hepatic veno-occlusive disease in children with high-risk solid tumors. Cho, EJ; Chueh, HW; Kim, JY; Koo, HH; Lee, SH; Sung, KW; Yoo, KH, 2012)	1.39
"Deferasirox treatment during induction chemotherapy reduces the frequency of VOD during HDCT/autoSCT. "	( Iron chelation treatment with deferasirox prior to high-dose chemotherapy and autologous stem cell transplantation may reduce the risk of hepatic veno-occlusive disease in children with high-risk solid tumors. Cho, EJ; Chueh, HW; Kim, JY; Koo, HH; Lee, SH; Sung, KW; Yoo, KH, 2012)	2.11
"Deferasirox treatment for 3 or more years reversed or stabilized liver fibrosis in 83% of patients with iron-overloaded β-thalassemia. "	( Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years. Brissot, P; Cappellini, MD; Deugnier, Y; Giannone, V; Griffel, L; Porter, JB; Ropert, M; Turlin, B; Zhang, Y, 2011)	2.04
"The deferasirox treatment reduced pretreatment ferritin levels below the level of 1,000 ng/mL in a median period of 94 days, and these data were found to be statistically significant (p < 0.05)."	( Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT). Bahcebasi, S; Cetin, M; Deniz, K; Eser, B; Kaynar, L; Kurnaz, F; Ozturk, A; Pala, C; Sivgin, S; Unal, A; Uzer, E, 2012)	1.15
"Deferasirox treatment reduced liver iron content 51%."	( Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Aguilar, MI; Gonzalez, I; Moats, R; Nelson, M; Nick, H; Otto-Duessel, M; Shimada, H; Wood, JC, 2006)	2.5
"Deferasirox treatment also enhanced the host inflammatory response to mucormycosis."	( The iron chelator deferasirox protects mice from mucormycosis through iron starvation. Edwards, JE; French, SW; Fu, Y; Gebermariam, T; Husseiny, MI; Ibrahim, AS; Lin, L; Schwartz, J; Skory, CD; Spellberg, BJ, 2007)	1.39
"Treatment with deferasirox for up to 2 years yielded a sustained reduction in iron burden, with a clinically manageable safety profile."	( Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia. Cappellini, MD; Taher, AT; Temraz, S, 2013)	2.17
"Treatment with deferasirox resulted in a statistically significant (p< 0.01) decrease in plasma ferritin levels as compared to the control group (823 ng/ml ± 56 and 1220 ng/ml ±114, respectively)."	( Deferasirox limits cartilage damage following haemarthrosis in haemophilic mice. Biesma, DH; Coeleveld, K; Lafeber, FP; Mastbergen, SC; Nieuwenhuizen, L; Roosendaal, G; Schutgens, RE, 2014)	2.18
"Treatment with deferasirox produced a significant reduction in median serum ferritin levels in chelation-naïve patients with MDS from 2679 to 2000 ng/mL (P = 0.0002) and a pronounced decrease in prechelated patients with MDS from 2442 to 2077 ng/mL (P = 0.06)."	( Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange. Blumenstengel, K; Gattermann, N; Germing, U; Goebeler, M; Groschek, M; Jarisch, A; Junkes, A; Leismann, O; Losem, C; Procaccianti, M; Schlag, R, 2012)	2.16
"Treatment with deferasirox significantly improves left ventricular function."	( Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients. Brevi, F; Cappellini, MD; Cassinerio, E; Graziadei, G; Milazzo, A; Pattoneri, P; Pedrotti, P; Roghi, A; Zanaboni, L, 2012)	0.72
"Treatment with deferasirox alone ameliorated anaemia and normalized the serum iron levels and hepatic iron concentration in the animals."	( Iron chelation therapy as a treatment for Pythium insidiosum in an animal model. Alves, SH; Fighera, RA; Flores, MM; Pilotto, MB; Santurio, JM; Weiblen, C; Wolkmer, P; Zanette, RA, 2013)	0.73

Excerpt	Reference	Relevance
" Primary objectives included assessment of safety and tolerability (measured by adverse events and clinical laboratory monitoring), pharmacokinetics (measured as drug and drug-iron complex), and cumulative net iron excretion (measured by faecal and urine output minus food input)."	( Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Alberti, D; Anderson, JR; Giardina, PJ; Grady, RW; Krebs-Brown, AJ; Nathan, DG; Neufeld, EJ; Nisbet-Brown, E; Olivieri, NF; Séchaud, R; Sizer, KC, 2003)	0.32
" This article speculates that cyclosporine eye drops would also be useful for any disease causing ectropion or eclabion of the eye as well as toxic epidermal necrolysis-related eye pathology (in particular corneal scarring)."	( A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine. Scheinfeld, N, 2007)	0.72
" In the interim, 1-year data show that deferasirox was well tolerated, with generally infrequent and mild adverse events."	( A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan. Hata, T; Ishikawa, T; Kato, J; Kondo, M; Miyazawa, K; Mori, H; Nakao, S; Ohyashiki, K; Omine, M; Ozawa, K; Rojkjaer, L; Taniguchi, J; Tanii, H; Tatsumi, Y; Urabe, A, 2008)	0.85
" However, despite these fatalities it would appear that there is no regular monitoring of such toxicities or of effects such as the accumulation of toxic metals."	( Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients. Kontoghiorghes, GJ, 2008)	0.59
" Deferasirox is generally well tolerated, with the most common adverse events being gastrointestinal disturbances and rash."	( Long-term efficacy and safety of deferasirox. Cappellini, MD, 2008)	1.54
" Drug-related adverse events were mostly mild to moderate and resolved without discontinuing treatment."	( Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Al Jefri, A; Al Zir, K; Daar, S; El-Beshlawy, A; Elalfy, MS; Habr, D; Hmissi, A; Kriemler-Krahn, U; Taher, A, 2009)	0.66
" The only adverse effects attributable to deferasirox were rashes in two patients."	( Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Andes, D; Anglim, A; Bonilla, H; Ibrahim, AS; Mathisen, GE; Perez, M; Spellberg, B; Walsh, TJ, 2009)	0.9
" The adverse event profile in patients who received deferasirox doses of >30 mg/kg per d was consistent with previously published data."	( Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Cappellini, MD; Clark, J; Galanello, R; Habr, D; Lawniczek, T; Piga, A; Porter, JB; Taher, A; Vichinsky, E, 2009)	0.91
"Therapy with deferasirox is safe in paediatric patients with thalassaemia major."	( Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major. Chandra, J; Chaudhary, H; Dutta, AK; Pemde, H; Singh, V, 2011)	1.05
" The most common reasons for discontinuation were withdrawal of consent (23·8%), lost to follow-up (9·2%) and adverse events (AEs) (7·6%)."	( Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Bernaudin, F; Coates, T; Deng, W; Forni, GL; Gardner, R; Giannone, V; Griffel, L; Hassell, K; Heeney, MM; Inusa, B; Kutlar, A; Lane, P; Mathias, L; Porter, J; Tebbi, C; Vichinsky, E; Wilson, F, 2011)	0.65
"7%) discontinued because of adverse events."	( Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Agaoglu, L; Aydinok, Y; Bejaoui, M; Canatan, D; Cappellini, MD; Capra, M; Clark, J; Cohen, A; Dong, V; Drelichman, G; Economou, M; Fattoum, S; Griffel, L; Kattamis, A; Kilinc, Y; Perrotta, S; Piga, A; Porter, JB, 2011)	0.69
" The DFX treatment-related adverse events were observed."	( [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major]. Chen, GF; Chen, JJ; Gao, HY; Li, CG; Li, Q, 2011)	0.65
" Serum liver transaminase elevation was the most common adverse effect, followed by non-progressive elevation in serum creatinine level."	( [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major]. Chen, GF; Chen, JJ; Gao, HY; Li, CG; Li, Q, 2011)	0.65
" Serum liver transaminase elevation and non-progressive elevation in serum creatinine level are major adverse effects in DFX treatment."	( [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major]. Chen, GF; Chen, JJ; Gao, HY; Li, CG; Li, Q, 2011)	0.65
" Adverse effect of DFX included diarrhea, maculopapular skin rash and transient proteinuria that necessitated temporary stoppage of medication."	( Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia. Ahmed, J; Jankharia, B; Krishnan, P; Merchant, R, 2012)	0.69
" The most common adverse effects were nausea and vomiting, which occurred in three of the patients (13%)."	( Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT). Bahcebasi, S; Cetin, M; Deniz, K; Eser, B; Kaynar, L; Kurnaz, F; Ozturk, A; Pala, C; Sivgin, S; Unal, A; Uzer, E, 2012)	0.67
" Serum ferritin (SF) was measured monthly, and safety assessment included monitoring of adverse events during treatment and of liver and renal parameters."	( Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population. Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A, 2012)	1.82
" The most common adverse events (≥ 10 % of all patients) with suspected drug relationship were diarrhea (n = 25, 46 %), nausea (n = 13, 24 %), upper abdominal pain (n = 8, 15 %), serum creatinine increase (n = 16, 30 %) and rash (n = 5, 9 %)."	( Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Baier, M; Gattermann, N; Giagounidis, A; Haase, D; Höchsmann, B; Hofmann, WK; Junkes, A; Leismann, O; Lübbert, M; Lück, A; Nolte, F; Platzbecker, U; Schrezenmeier, H; Schumann, C; Taupitz, M, 2013)	0.6
" Adverse events (AEs) and laboratory parameters were monitored throughout."	( Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Aydinok, Y; Chan, LL; El-Beshlawy, A; Elalfy, MS; Habr, D; Lee, SH; Martin, N; Porter, JB; Sutcharitchan, P; Taher, AT, 2013)	0.7
" None of the patients presented any serious adverse effects and the treatment was well tolerated."	( Safety and efficacy of 4 years of deferasirox treatment for sickle cell disease patients. Bekiari, E; Mainou, M; Tsapas, A; Vetsiou, E; Vlachaki, E, 2013)	0.67
" Plasma concentration observed at 15 mg/kg was well above that expected for this dose (40-50 μmol/L), although no adverse clinical events were observed."	( Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis. Batty, KT; Ferrari, P; Maker, GL; Olynyk, JK; Siva, B; Trengove, RD, 2013)	0.68
"A record 4113 fatalities were reported in 2012 in a postmarketing surveillance of patients treated with deferasirox, despite warnings of life-threatening toxic side effects, and the need for regular monitoring and prophylactic measures."	( A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? Kontoghiorghes, GJ, 2013)	0.84
" The Fisher's Exact test was used to compare the frequency of subjects who experienced at least one SCA-related adverse event (AE) or serious adverse event (SAE) in each arm and to compare event rates."	( Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Alvarez, O; Aygun, B; Bonner, M; Flanagan, J; Lockhart, A; Miller, ST; Mueller, BU; Owen, W; Schultz, W; Scott, JP; Ware, RE; Yovetich, NA, 2013)	0.39
" Adverse events (AEs) secondary to drug administration were reported in 26."	( Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. Barrette, S; Files, B; Habr, D; Minniti, CP; Torres, M; Vichinsky, E; Zhang, Y, 2013)	0.7
" Two independent authors assessed data from extracted randomized trials for efficacy and safety in the measurements of serum ferritin (SF), live iron concentration (LIC), myocardial iron content (MIC), left ventricular ejection fraction (LVEF) and adverse events (AEs)."	( Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. Huang, L; Jiang, H; Xia, S; Zhang, W, 2013)	0.63
"Findings indicated that the most effective and safe iron chelators remains to be proven, and further large-scale, long-term studies are needed."	( Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. Huang, L; Jiang, H; Xia, S; Zhang, W, 2013)	0.63
" The most common adverse events were skin rash and gastrointestinal disturbance."	( Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran. Abdollah Gorji, F; Alavi, S; Arzanian, MT; Ebadi, M; Ghazizadeh, F; Shamsian, B, 2014)	0.71
"Deferasirox proved as an efficient and safe chelating agent in our patients, specifically in mild to moderate iron overloaded patients."	( Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran. Abdollah Gorji, F; Alavi, S; Arzanian, MT; Ebadi, M; Ghazizadeh, F; Shamsian, B, 2014)	2.16
" Of 84 patients who discontinued deferasirox therapy, 22 died during the trial, and 28 withdrew due to an adverse event (AE)."	( Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). Alimena, G; Angelucci, E; Borin, L; Caocci, G; Cilloni, D; Di Tucci, AA; Fazi, P; Fenu, S; Finelli, C; Latte, G; Molteni, A; Piciocchi, A; Quaresmini, G; Quarta, G; Rivellini, F; Salvi, F; Sanpaolo, G; Santini, V; Storti, S; Tura, S; Vallisa, D; Vignetti, M; Volpe, A; Voso, MT, 2014)	2.13
" However, the US Food and Drug Administration issued a warning about the potential adverse events associated with DFX in 2010."	( Safety of deferasirox: a retrospective cohort study on the risks of gastrointestinal, liver and renal events. Chou, HC; Hsiao, FY; Huang, WF; Tsai, YW, 2014)	0.8
" The risks of different adverse events were individually analyzed by Cox proportional hazards models and adjusted by age, sex, concomitant medications, and prior medical conditions."	( Safety of deferasirox: a retrospective cohort study on the risks of gastrointestinal, liver and renal events. Chou, HC; Hsiao, FY; Huang, WF; Tsai, YW, 2014)	0.8
" More researches are warranted to evaluate the association between DFX use and potential adverse events."	( Safety of deferasirox: a retrospective cohort study on the risks of gastrointestinal, liver and renal events. Chou, HC; Hsiao, FY; Huang, WF; Tsai, YW, 2014)	0.8
" Drug-related adverse events, reported in 17 patients (56."	( Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation. Batlle, M; Belloch, V; Duarte, R; Hernández, D; Jarque, I; Jiménez, M; Jiménez, S; López, J; Rovira, M; Sampol, A; Solano, C; Valcárcel, D; Vallejo, C; Vázquez, L, 2014)	0.65
" Nephrotoxicity is the most serious and frequent adverse effect of deferasirox treatment."	( Deferasirox nephrotoxicity-the knowns and unknowns. Díaz-García, JD; Gallegos-Villalobos, A; Gonzalez-Espinoza, L; Ortiz, A; Sanchez-Niño, MD; Villarrubia, J, 2014)	2.08
"DFP/DFX combination proved superior in improving cardiac T2*, treatment compliance, and patients satisfaction with no greater adverse events."	( Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. Adly, AM; Elalfy, MS; Elhenawy, YI; Samir, A; Tony, S; Wali, Y, 2015)	0.65
" DFX was temporarily skipped for adverse events in seven patients (7."	( Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload. Bae, SH; Chung, JS; Hyun, MS; Joo, YD; Kim, H; Kim, HG; Kim, IH; Kim, SH; Kim, YS; Kwon, KY; Lee, GW; Lee, HS; Lee, SM; Lee, WS; Lim, SN; Moon, JH; Park, KT; Ryoo, HM; Sohn, SK, 2015)	0.73
" The most common investigator-reported drug-related adverse events (AEs) were increased blood creatinine (26."	( Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation. Al-Ali, HK; Albrecht, S; Altamura, S; Bug, G; de Haas, K; Hubert, K; Jaekel, N; Kröger, N; Leismann, O; Lieder, K; Muckenthaler, MU; Niederwieser, D; Platzbecker, U; Stadler, M, 2016)	0.74
" The most common adverse events (AEs) were increased serum creatinine levels (40."	( [Efficacy and safety of deferasirox in aplastic anemia patients with iron overload: a single arm, multi-center,prospective study in China]. Chang, H; Hu, D; Hu, L; Huang, J; Liu, F; Nie, N; Quan, R; Shao, Y; Shi, J; Tang, X; Xiao, H; Zhang, F; Zhang, J; Zhang, L; Zheng, C; Zheng, Y; Zhou, Y, 2016)	0.74
" The drug was well tolerated with a clinically manageable safety profile and no major adverse events."	( [Efficacy and safety of deferasirox in aplastic anemia patients with iron overload: a single arm, multi-center,prospective study in China]. Chang, H; Hu, D; Hu, L; Huang, J; Liu, F; Nie, N; Quan, R; Shao, Y; Shi, J; Tang, X; Xiao, H; Zhang, F; Zhang, J; Zhang, L; Zheng, C; Zheng, Y; Zhou, Y, 2016)	0.74
" Selected protocols using DFO, L1, and their combination can be designed for personalized chelation therapy in TI, which can effectively and safely remove all the excess toxic iron and prevent cardiac, liver, and other organ damage."	( Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Kontoghiorghe, CN; Kontoghiorghes, GJ, 2016)	0.66
" At every visit for blood transfusion, all patients were clinically assessed for any adverse effects; liver and renal functions were monitored 6-monthly."	( Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia. Gomber, S; Jain, P; Narang, M; Sharma, S, 2016)	0.43
" No significant adverse reactions were noticed in either the monotherapy or the combination group."	( Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia. Gomber, S; Jain, P; Narang, M; Sharma, S, 2016)	0.43
"Oral combination therapy of deferiprone and deferasirox appears to be an efficacious and safe modality to reduce serum ferritin in multi-transfused children with thalassemia."	( Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia. Gomber, S; Jain, P; Narang, M; Sharma, S, 2016)	0.7
" Adverse effects of deferasirox have been reported in large prospective studies."	( Proximal muscular atrophy and weakness: An unusual adverse effect of deferasirox iron chelation therapy. Albert, MH; Blaschek, A; Gerstl, L; Huetker, S; Müller-Felber, W; Teusch, V; Vill, K, )	0.69
" The majority of patients (81%) were affected by at least 1 adverse event, with decreased renal creatinine clearance being the most frequent."	( CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload. Bruch, HR; Dencausse, Y; Heßling, J; Michl, G; Schlag, R; Schneider-Schranz, C; Schulte, C; Skorupa, A; Tesch, H; Wolf, S, 2016)	0.67
"Deferasirox adverse effects include the following: gastrointestinal disturbance, mild elevations in serum creatinine levels and intermittent proteinuria; these events are dose-dependent and reversible with drug discontinuation, but this solution can lead to an inadequate iron chelation."	( Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment. Allegra, S; Cusato, J; D'Avolio, A; De Francia, S; Massano, D; Piga, A; Pirro, E, 2016)	3.32
" The combination of drugs was well tolerated and no new adverse effects were observed."	( Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With β-Thalassemia Major: An Experience From North India. Chandra, J; Dhingra, B; Jain, R; Mahto, D; Parakh, N; Sharma, S, 2017)	0.69
" A total of 134 adverse events (AEs) were reported in 25 patients (92."	( A Phase II, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major. Dag, I; Ertem, M; Karasu, G; Kaya, Z; Kuskonmaz, BB; Ozudogru, O; Uygun, V; Yesilipek, MA, 2018)	0.71
" Random effects model was used to generate direct, indirect and mixed treatment comparison pooled estimates for the following outcomes: serum ferritin, liver iron concentration (LIC), changes in serum ferritin, mortality, urine iron excretion, adverse events, neutropenia, agranulocytosis and number of patients withdrawing the chelating therapy."	( Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. Sivaramakrishnan, G; Sridharan, K, 2018)	0.48
" DFP/DFO was associated with higher LVEF, low risk of adverse events and reduced end of serum ferritin compared to DFO."	( Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. Sivaramakrishnan, G; Sridharan, K, 2018)	0.48
" Particular attention was paid to mortality, serum ferritin (SF), liver iron concentration (LIC), myocardial iron concentration, and adverse events (AEs)."	( Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis. Chen, G; Dou, H; Qin, Y; Zhao, Y, 2019)	0.81
" We compared changes in liver and heart iron, adverse effects and other outcomes, in patients treated with deferiprone or deferasirox."	( Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox. Gallie, BL; Olivieri, NF; Sabouhanian, A, 2019)	0.93
" Close monitoring of the patients is necessary to detect and manage any possible adverse events."	( Evaluation of Efficacy, Safety, and Satisfaction Taking Deferasirox Twice Daily Versus Once Daily in Patients With Transfusion-Dependent Thalassemia. Ansari, S; Azarkeivan, A; Bahoush, G; Bazrafshan, A; Haghpanah, S; Jangjou, A; Karimi, M; Shahsavani, A, 2020)	0.8
" No significant difference between the groups was shown in the occurrence of serious and drug-related adverse events."	( Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. Bejaoui, M; Bonifazi, D; Ceci, A; Christou, S; Cosmi, C; Cuccia, L; Del Vecchio, GC; Della Pasqua, O; El-Beshlawy, A; Felisi, M; Filosa, A; Hassab, H; Kattamis, A; Kreka, M; Maggio, A; Origa, R; Putti, MC; Reggiardo, G; Sherief, L; Spino, M; Telfer, P; Tempesta, B; Tricta, F; Tsang, YC; Vitrano, A; Zaka, A, 2020)	0.79
"In paediatric patients with transfusion-dependent haemoglobinopathies, deferiprone was effective and safe in inducing control of iron overload during 12 months of treatment."	( Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. Bejaoui, M; Bonifazi, D; Ceci, A; Christou, S; Cosmi, C; Cuccia, L; Del Vecchio, GC; Della Pasqua, O; El-Beshlawy, A; Felisi, M; Filosa, A; Hassab, H; Kattamis, A; Kreka, M; Maggio, A; Origa, R; Putti, MC; Reggiardo, G; Sherief, L; Spino, M; Telfer, P; Tempesta, B; Tricta, F; Tsang, YC; Vitrano, A; Zaka, A, 2020)	0.79
" They were also monitored monthly for any adverse effects."	( Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study. Delhikumar, CG; DivakarJose, RR; Ram Kumar, G, 2021)	0.86
" The drugs were tolerated well without any serious adverse effects."	( Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study. Delhikumar, CG; DivakarJose, RR; Ram Kumar, G, 2021)	0.86
" Twenty-nine patients who used an alternative chelator either alone or combined, who were not compliant to the treatment, changed the drug due to adverse reactions, and had multiple transfusions and did not complete 4 years of DFX use were excluded."	( Safety and efficacy of deferasirox in patients with transfusion-dependent thalassemia: A 4-year single-center experience. Akıcı, F; Arslantaş, E; Ayçiçek, A; Aydoğan, G; Bayram, C; Odaman Al, I; Özdemir, GN; Şalcıoğlu, Z; Uysalol, EP; Zengin Ersoy, G, 2021)	0.93

Excerpt	Reference	Relevance
"5 to 80 mg/kg to investigate its safety, tolerability, and pharmacokinetics and to obtain preliminary information on pharmacodynamic effects."	( Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. Alberti, D; Bigler, H; Galanello, R; Piga, A; Rouan, MC; Séchaud, R, 2003)	0.32
" Pharmacokinetic parameters assessed at the end of each treatment period were compared using the standard statistical analysis for bioequivalence assessment."	( Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin. Balez, S; Belleli, R; Robeva, A; Sechaud, R, 2008)	0.62
" Cmax, volume of distribution/bioavailability (Vd/F), and elimination half-life (t(1/2)) were not different between the groups, suggesting bioavailability as the likely discriminant."	( Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Bergmann, AK; Braunstein, J; Chirnomas, D; Finkelstein, Y; Grant, FD; Neufeld, EJ; Paley, C; Pereira, L; Shannon, M; Smith, AL, 2009)	1.8
" Absorption, distribution, metabolism, and excretion of [14C]deferasirox at pharmacokinetic steady state was investigated in five adult beta-thalassemic patients."	( Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Bruin, GJ; Glaenzel, U; Hazell, K; Porter, JB; Sechaud, R; Waldmeier, F; Warrington, S, 2010)	0.86
"In addition to the pharmacokinetic and pharmacodynamic profile of deferasirox, this review examines the efficacy and safety data from pivotal studies with deferasirox in iron-overloaded patients with various anemias, including thalassemia, sickle cell disease and myelodysplastic syndromes."	( Deferasirox: pharmacokinetics and clinical experience. Campus, S; Galanello, R; Origa, R, 2012)	2.06
" Concomitant hydroxyurea administration (n = 28) did not appear to influence the efficacy, safety (including liver and kidney function), and pharmacokinetic parameters of deferasirox."	( Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. Barrette, S; Files, B; Habr, D; Minniti, CP; Torres, M; Vichinsky, E; Zhang, Y, 2013)	0.89
" However, the pharmacokinetic (PK) disposition of DEFR and the iron-DEFR complex (Fe-[DEFR]2) in this dosing strategy is unclear."	( Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration. Chiang, PH; Kuo, PH; Lai, CW; Lin, KH; Lu, MY; Wang, N; Wu, TH; Wu, WH, 2015)	0.69
" Deferasirox is a once-daily orally active tridentate selective iron chelator which pharmacokinetic disposition could influence treatment efficacy and toxicity."	( Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients. Allegra, S; Cusato, J; D'Avolio, A; De Francia, S; Massano, D; Piga, A; Pirro, E, 2017)	2.81
"Concerning pharmacokinetic parameters, a higher interindividual variability was shown."	( Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment. Allegra, S; Cusato, J; D'Avolio, A; De Francia, S; Massano, D; Piga, A; Pirro, E, 2016)	1.88
" Area under deferasirox concentration curve over 24h (AUC) values were determined by the mixed log-linear rule, using Kinetica software."	( Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia. Allegra, S; Arduino, A; Cusato, J; D'Avolio, A; De Francia, S; Longo, F; Massano, D; Piga, A; Pirro, E, 2016)	2.26
"025) and area under the concentration curve (P=0."	( Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children. Allegra, S; Cusato, J; D'Avolio, A; De Francia, S; Longo, F; Massano, D; Piga, A; Pirro, E, 2018)	0.73
"-24 C>T was associated with the pharmacokinetic variability of deferasirox in Chinese subjects."	( ABCC2 c.-24 C>T single-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects. Cao, K; Chen, X; Li, N; Lu, C; Lu, Y; Ren, G; Tan, Y; Wang, Y; Zhang, Y; Zhao, D; Zhou, J, 2020)	1.01
" This study investigated the effects of genetic polymorphisms on the pharmacokinetics of deferasirox in healthy Chinese subjects and constructed a pharmacokinetic prediction model based on physiologic factors and genetic polymorphism data."	( Effect of Genetic Polymorphisms on the Pharmacokinetics of Deferasirox in Healthy Chinese Subjects and an Artificial Neural Networks Model for Pharmacokinetic Prediction. Chen, J; Hu, Y; Jiang, B; Lou, H; Ruan, Z; Shao, R; Xu, Y; Yang, D, 2020)	1.02
" The plasma defersirox concentration was determined using a validated liquid chromatography-tandem mass spectrometry method, and pharmacokinetic parameters were calculated using the noncompartmental method."	( Effect of Genetic Polymorphisms on the Pharmacokinetics of Deferasirox in Healthy Chinese Subjects and an Artificial Neural Networks Model for Pharmacokinetic Prediction. Chen, J; Hu, Y; Jiang, B; Lou, H; Ruan, Z; Shao, R; Xu, Y; Yang, D, 2020)	0.8

Excerpt	Reference	Relevance
" Therefore, we sought to explore the synergistic effects and possible mechanisms of DFX combination with ELT in MDS cells."	( Deferasirox combination with eltrombopag shows anti-myelodysplastic syndrome effects by enhancing iron deprivation-related apoptosis. Fu, R; Huang, L; Liu, C; Liu, Z; Tian, M, 2022)	2.16
" Hydroxyurea, when combined with iron chelators such as DFX, provides an additional benefit of iron chelation in patients receiving chronic transfusion therapy."	( Iron Chelators, Such as Deferasirox, When Combined With Hydroxyurea, Provide an Additional Benefit of Iron Chelation in Patients Receiving Chronic Transfusion Therapy. Delicou, S; Koskinas, J; Manganas, K; Xydaki, A, 2022)	1.03

Excerpt	Reference	Relevance
" This was followed by a pharmacokinetic study to assess the relative bioavailability of deferasirox tablets dispersed in two types of soft drinks, dispersed in water, and without dispersion."	( Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. Balez, S; Brun, E; Dumortier, T; Dutreix, C; Morisson, S; Pommier, F; Séchaud, R, 2008)	0.86
" Therefore, the oral bioavailability of deferasirox tablets was not affected neither by the degree of dispersion nor by the type of drink (orange or apple juice versus water) used for dispersion."	( Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. Balez, S; Brun, E; Dumortier, T; Dutreix, C; Morisson, S; Pommier, F; Séchaud, R, 2008)	0.91
"This study shows that deferasirox bioavailability is unaltered when dispersed with orange or apple juice compared with dispersion in water."	( Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. Balez, S; Brun, E; Dumortier, T; Dutreix, C; Morisson, S; Pommier, F; Séchaud, R, 2008)	0.95
" The bioavailability of deferasirox was determined following a single oral dose (20 mg/kg) under fed and fasted conditions in patients."	( Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. Alberti, D; Balez, S; Belleli, R; Cappellini, MD; Dutreix, C; Ford, JM; Forni, GL; Galanello, R; Origa, R; Piga, A; Rivière, GJ; Séchaud, R; Zappu, A, 2008)	0.9
" The current study evaluated the absolute bioavailability of a single 375-mg oral dose of deferasirox administered in the form of tablets compared with a 130-mg intravenous infusion of deferasirox."	( Absolute oral bioavailability and disposition of deferasirox in healthy human subjects. Balez, S; Belleli, R; Robeva, A; Séchaud, R, 2008)	0.82
" bioavailability was 26% at the 10 mg/kg dose and showed an overproportional increase at the 100 mg/kg dose, probably because of saturation of elimination processes."	( Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. Boernsen, KO; Bruin, GJ; Faller, T; Nick, H; Schneider, J; Schweitzer, A; Waldmeier, F; Wiegand, H, 2008)	0.59
" Cmax, volume of distribution/bioavailability (Vd/F), and elimination half-life (t(1/2)) were not different between the groups, suggesting bioavailability as the likely discriminant."	( Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Bergmann, AK; Braunstein, J; Chirnomas, D; Finkelstein, Y; Grant, FD; Neufeld, EJ; Paley, C; Pereira, L; Shannon, M; Smith, AL, 2009)	1.8
" A promising method to improve the bioavailability of pharmaceutical agents is the rapid expansion of supercritical solutions."	( Formation of ultrafine deferasirox particles via rapid expansion of supercritical solution (RESS process) using Taguchi approach. Asghari, I; Esmaeilzadeh, F, 2012)	0.69
" In this study, we have conjugated DFOB to derivatives of adamantane or the clinical iron chelator deferasirox to produce lipophilic compounds designed to increase the bioavailability of DFOB to brain cells."	( Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease. Codd, R; Crouch, PJ; Ganio, G; Liddell, JR; Liu, J; Mok, SS; Obando, D; Volitakis, I; White, AR, 2013)	0.91
" This finding enriches our bioinspired drug design strategy for Ti(IV)-based anticancer therapeutics, which applies a family of Fe(III) chelators termed chemical transferrin mimetic (cTfm) ligands to inhibit Fe bioavailability in cancer cells."	( Expanding the Therapeutic Potential of the Iron Chelator Deferasirox in the Development of Aqueous Stable Ti(IV) Anticancer Complexes. Benjamín-Rivera, JA; Delgado, Y; Loza-Rosas, SA; Munet-Colón, C; Negrón, LJ; Parks, TB; Rivero, KI; Tinoco, AD; Vázquez-Maldonado, AL; Vázquez-Salgado, AM, 2017)	0.7
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Low bioavailability of the drug due to insufficient solubility in physiological fluids is the main drawback of DFX."	( Solid Dispersion Pellets: An Efficient Pharmaceutical Approach to Enrich the Solubility and Dissolution Rate of Deferasirox. Abbaspour, M; Ebrahimnejad, P; Farmoudeh, A; Nokhodchi, A; Rezaeiroshan, A, 2020)	0.77

Excerpt	Relevance	Reference
" Patients were randomized and received treatment with deferasirox (n = 296) or deferoxamine (n = 290), with dosing of each according to baseline liver iron concentration (LIC)."	( A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Agaoglu, L; Alberti, D; Athanassiou-Metaxa, M; Aydinok, Y; Bejaoui, M; Cappellini, MD; Capra, M; Coates, T; Cohen, A; Drelichman, G; Fattoum, S; Galanello, R; Giardina, P; Janka-Schaub, G; Kattamis, A; Kilinc, Y; Kourakli-Symeonidis, A; Magnano, C; Marks, P; Olivieri, N; Opitz, H; Perrotta, S; Piga, A; Porter, J; Ressayre-Djaffer, C; Thuret, I; Verissimo, M; Vermylen, C, 2006)	0.91
"To review the available literature on the pharmacology, pharmacokinetics, efficacy, toxicology, adverse effects, drug interactions, and dosage guidelines for deferasirox, an oral iron chelator, in Phase III trials."	( Deferasirox--an oral agent for chronic iron overload. Hagemann, TM; Vanorden, HE, 2006)	1.97
" Pharmacokinetic data support a once-daily dosing regimen based on body weight."	( Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Alberti, D; Belleli, R; Bertrand, Y; Bordone, E; Forni, GL; Foschini, ML; Galanello, R; Hewson, N; Lavagetto, A; Leoni, G; Longo, F; Maseruka, H; Piga, A; Sechaud, R; Zappu, A, 2006)	0.62
" Clinical phase I and II studies demonstrated an exclusively fecal route of iron excretion, with a long plasma half-life, suitable for once-daily dosing and 24-hour protection from labile iron."	( Deferasirox: An effective once-daily orally active iron chelator. Porter, JB, 2006)	1.78
"Daily divided dosing of deferasirox changes the relative cardiac and liver iron chelation profile compared with daily single dosing, trading improvements in cardiac iron elimination for less-effective hepatic chelation."	( Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy. Aguilar, M; Moats, R; Nick, H; Otto-Duessel, M; Wood, JC, 2007)	0.91
" Dosage was determined by baseline liver iron concentration (LIC)."	( Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Alberti, D; Alimena, G; Cappellini, MD; Cario, H; Cazzola, M; Cunningham, MJ; Debusscher, L; Della Porta, M; Ford, JM; Forni, GL; Galanello, R; Gathmann, I; Gattermann, N; Giardina, P; Greenberg, P; Jeng, M; Kwiatkowski, J; Maertens, J; Neufeld, EJ; Olivieri, N; Piga, A; Porter, J; Quarta, G; Rabault, B; Rose, C; Saglio, G; Soulières, D; Stadler, M; Tchernia, G; Vichinsky, E, 2008)	0.56
" Once-daily dosing with deferasirox > or =20 mg/kg/d provided sustained reduction in LPI levels in these heavily iron-overloaded patients, suggesting 24-h protection from LPI."	( Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Daar, S; Habr, D; Hmissi, A; Kriemler-Krahn, U; Nick, H; Pathare, A; Taher, A, 2009)	0.91
" The flexible dosing regimen of deferasirox allows dose adjustments to be made in response to trends in serum ferritin, to changes in a patient's transfusional iron intake, and to the objectives of treatment, allowing the full benefit of transfusion therapy without the risks associated with iron overload."	( Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy. Garcia-Manero, G; Jabbour, E; Kantarjian, HM; Taher, A, 2009)	0.87
" Effective dosing regimens for inadequately responding patients to deferasirox must be determined."	( Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Bergmann, AK; Braunstein, J; Chirnomas, D; Finkelstein, Y; Grant, FD; Neufeld, EJ; Paley, C; Pereira, L; Shannon, M; Smith, AL, 2009)	2.03
"0001), reflecting dosage adjustments and ongoing iron intake."	( Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Cappellini, MD; Chan, LL; Domokos, G; El-Beshlawy, A; Elalfy, M; Gattermann, N; Giraudier, S; Habr, D; Kattamis, A; Lee, JW; Li, CK; Lin, KH; Porter, J; Rose, C; Roubert, B; Seymour, JF; Taher, A; Thein, SL; Viprakasit, V, 2010)	0.58
" Excluding the diagnostic dilemma of an improbable failure of DFX chelation, the pathogenesis of this phenomenon remains to be clarified, thus further complicating the problem of ferritin specificity and its role in monitoring chelation efficacy and in adapting DFX dosage in a limited period of treatment."	( Paradoxically increased ferritin level in a beta-thalassemia major patient following the start of deferasirox chelation therapy. Ammirabile, M; Cinque, P; Costantini, S; Di Matola, T; Prossomariti, L; Ricchi, P; Spasiano, A, 2010)	0.58
" Using a pre-specified dosing algorithm serum ferritin reduction was similar in both groups, mean difference (MD) 375."	( Deferasirox for managing transfusional iron overload in people with sickle cell disease. Antes, G; Bassler, D; Fleeman, N; Meerpohl, JJ; Niemeyer, C; Rücker, G, 2010)	1.8
"Patients from two Taiwanese hospitals with transfusion-dependent β-thalassemia, including those who showed increasing serum ferritin levels for six consecutive months, with at least one level >2,500 ng/dl, while treated with >30 mg/kg/day of once-daily deferasirox (unresponsive) or developed deferasirox-related adverse events (AEs) at the dosage required to maintain the iron burden balance (intolerant) and were treated twice-daily with the same total daily dose of deferasirox since 2008, were enrolled in the study and evaluated retrospectively by medical record review."	( Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia. Chang, HH; Chang, TT; Chiou, SS; Jou, ST; Liao, YM; Lin, DT; Lin, KH; Lin, PC; Lu, MY; Yang, YL, 2011)	0.81
"Twice-daily deferasirox dosing is effective in iron chelation and improves tolerability in transfusion-dependent β-thalassemia patients who are unresponsive to or intolerant of once-daily deferasirox."	( Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia. Chang, HH; Chang, TT; Chiou, SS; Jou, ST; Liao, YM; Lin, DT; Lin, KH; Lin, PC; Lu, MY; Yang, YL, 2011)	1.01
" The standard dosage is not useful to every patient."	( [Deferasirox--a new oral iron chelator--review]. Chen, BA; Gao, C; Wang, T, 2010)	1.27
" Iron burden was substantially reduced with appropriate dosing in patients treated for at least 4 years."	( Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Bernaudin, F; Coates, T; Deng, W; Forni, GL; Gardner, R; Giannone, V; Griffel, L; Hassell, K; Heeney, MM; Inusa, B; Kutlar, A; Lane, P; Mathias, L; Porter, J; Tebbi, C; Vichinsky, E; Wilson, F, 2011)	0.65
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."	( FDA-approved drug labeling for the study of drug-induced liver injury. Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)	0.37
"30 mL red blood cells/kg/d), mean deferasirox dosing (19."	( Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. Beris, P; Domokos, G; Forni, GL; Habr, D; Lin, KH; Porter, JB; Roubert, B; Taher, A; Thein, SL, 2011)	0.94
"Based on the current available data, deferasirox treatment is effective with a clinically manageable safety profile although appropriate dosing according to the severity of iron burden and iron intake, together with the careful monitoring of laboratory parameters and adverse events, is recommended."	( Deferasirox: pharmacokinetics and clinical experience. Campus, S; Galanello, R; Origa, R, 2012)	2.09
"The effect of deferasirox dosing tailored for iron burden and iron loading based on liver iron concentration (LIC) was assessed over 1 year in less versus more heavily iron-overloaded patients in a substudy of the Evaluation of Patients' Iron Chelation with Exjade®."	( Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Aydinok, Y; Chan, LL; El-Beshlawy, A; Elalfy, MS; Habr, D; Lee, SH; Martin, N; Porter, JB; Sutcharitchan, P; Taher, AT, 2013)	1.06
" These analyses also evaluated deferasirox dosing strategies for patients with NTDT."	( Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. Cappellini, MD; Chuncharunee, S; Galanello, R; Habr, D; Karakas, Z; Kattamis, A; Lawniczek, T; Porter, JB; Ros, J; Siritanaratkul, N; Sutcharitchan, P; Taher, AT; Viprakasit, V; Zhang, Y, 2013)	2.12
" The iron chelating treatment significantly reduced serum ferritin levels administered at a dosage of 20-30 mg/kg/day (p<0."	( The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload. Akyol, G; Baldane, S; Cetin, M; Eser, B; Kaynar, L; Keklik, M; Kurnaz, F; Pala, C; Sivgin, S; Unal, A; Zararsiz, G, 2013)	0.7
" Effective DFX dosage is thus defined by assessing the efficacy of this agent in clinical practice."	( Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload. Hikota, R; Horiuchi, T; Kato, S; Kimura, F; Kobayashi, A; Kobayashi, S; Maekawa, T; Osawa, Y; Sato, K; Watanabe, J; Yamamura, T, 2014)	0.64
" This review summarizes the clinical pharmacokinetics, pharmacodynamics, and drug-drug interaction profile of deferasirox, and the claims supporting once-daily dosing for effective chelation."	( Clinical pharmacology of deferasirox. Tanaka, C, 2014)	0.92
" Quantitative magnetic resonance imaging indicated that dosage escalations up to 100 mg/kg were needed to produce meaningful reductions in iron stores."	( Dose titration of deferasirox iron chelation therapy by magnetic resonance imaging for chronic iron storage disease in three adult red bald-headed uakari (Cacajao calvus rubicundus). Baer, J; Brewer, C; Garner, M; Stadler, CK; Tyszka, JM; Wood, JC, 2014)	0.74
" Individual patient-tailored dosing of DFX should help to improve iron chelation efficacy and to reduce dose-dependent drug toxicity."	( Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy? Forni, GL; Fucile, C; Marini, V; Martelli, A; Mattioli, F; Milano, G; Perrotta, S; Pinto, V; Puntoni, M; Robbiano, L, 2015)	0.76
" Plasma concentrations were determined at the end of dosing interval (C trough) using an high-performance liquid chromatography-ultraviolet method."	( Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. Allegra, S; Cusato, J; D'Avolio, A; De Francia, S; Massano, D; Piga, A, 2015)	0.67
" However, the pharmacokinetic (PK) disposition of DEFR and the iron-DEFR complex (Fe-[DEFR]2) in this dosing strategy is unclear."	( Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration. Chiang, PH; Kuo, PH; Lai, CW; Lin, KH; Lu, MY; Wang, N; Wu, TH; Wu, WH, 2015)	0.69
"Chromatographic analysis was performed using a solvent delivery system coupled to an HPLC-UV detector to determine the steady-state concentrations of DEFR (CDEFR) and Fe-(DEFR)2 (CFe-[DEFR]2) in β-thalassemia major patients (n = 8) following either once-daily or BID dosing, during which the PK parameters of the 2 dosing schedules were compared."	( Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration. Chiang, PH; Kuo, PH; Lai, CW; Lin, KH; Lu, MY; Wang, N; Wu, TH; Wu, WH, 2015)	0.69
"A total of 28 patients either dosing daily or twice daily were recruited."	( Deferasirox-Iron Complex Formation Ratio as an Indicator of Long-term Chelation Efficacy in β-Thalassemia Major. Chiang, PH; Kuo, PH; Lin, KH; Lin, TH; Lu, MY; Wang, N; Wu, TH; Wu, WH, 2017)	1.9
" The pooled effects across the different dosing ratios are: serum ferritin, mean difference (MD) 454."	( Deferasirox for managing iron overload in people with thalassaemia. Allert, R; Bassler, D; Bollig, C; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK, 2017)	1.9
" Drug plasma concentrations at the end of dosing interval (Ctrough) and after 0, 2, 4, 6, and 24 h of drug administration were measured by a HPLC-UV method."	( Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children. Allegra, S; Cusato, J; D'Avolio, A; De Francia, S; Longo, F; Massano, D; Piga, A; Pirro, E, 2018)	0.73
" Our dose escalating method of deferasirox is useful to identify the optimal dosage of the drug in each patient."	( Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302). Kanamori, H; Kanda, J; Kanda, Y; Koyama, S; Machida, S; Miyazaki, T; Morita, S; Najima, Y; Okamoto, S; Saito, T; Tachibana, T; Takeuchi, M; Tanaka, M; Yamamoto, E, 2018)	2.21
"Whilst only moderately effective at a dosage of 1000mg/day, deferasirox may be a safe agent for iron removal in iron overloaded peritoneal dialysis patients, as relatively low dialysate iron levels reduces the risk of Yersinia and Rhizopus infection."	( Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients. Doery, JC; Kaplan, Z; Kerr, PG; Yii, E, 2018)	1.18
" Dose adjustments were reported in 48% of the patients with dose-escalation strategies being the most frequent reason for dosage increases (49%)."	( Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study. Albrecht, S; Geer, T; Hebart, H; Hofmann, WK; Jarisch, A; Johr, C; Nolte, F; Nückel, H; Rubanov, O; Schmidt, B; Schumann, C, 2018)	0.77
" Preventing and successfully managing AEs may help limit their impact on adherence, and following dosage and administration recommendations for iron chelators such as deferasirox may help minimise AEs and optimise treatment in patients with transfusion-dependent thalassaemia and lower-risk MDS."	( Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes. Aydinok, Y; Kattamis, A; Taher, A, 2018)	0.98
" Regular monitoring and an adjusted deferasirox dosing strategy per local labels allowed continued iron chelation treatment and control of transfusional iron in the majority of patients on study."	( International sentinel site surveillance of patients with transfusional hemosiderosis treated with deferasirox in actual practice setting. Azmon, A; Beneitez Pastor, D; Bruederle, A; El-Beshlawy, A; Elalfy, M; Gilotti, G; Inusa, B; Soledada Duran Nieto, M; Xicoy, B, 2019)	1.01
" Group II consisted of 19 people with severe thallium salt poisoning, which in addition to the above treatment, received Deferasirox in a dosage of 500 mg two times per day per os."	( Complexions therapy and severe intoxication by Thallium salts. Babaskina, L; Rayisyan, M; Zakharova, N, 2021)	0.83
" In the literature, there were three studies showing the boon of twice in a day dosing of deferasirox among transfusional-dependent beta thalassemia patients."	( Effectiveness and tolerability of twice daily dosing of deferasirox in unresponsive and intolerant transfusion-dependent beta-thalassemia patients: A narrative review. Babu, T; Panachiyil, GM; Ravi, MD; Sebastian, J, )	0.6
" Total annual exposure to DFX was calculated after 12 months and expressed as the accumulated exposure time at a dosage of 20 mg/kg/day."	( Dose of deferasirox correlates with its effects, which differ between low-risk myelodysplastic syndrome and aplastic anaemia. Han, B; Zhang, R, 2022)	1.16
" The minimum dosage of DFX needed for a significant serum ferritin (SF) decrease was 20 mg/kg/day at 6 months, and the minimum accumulation of DFX had to reach 9 months at 20 mg/kg/day by 12 months for patients with low-risk MDS."	( Dose of deferasirox correlates with its effects, which differ between low-risk myelodysplastic syndrome and aplastic anaemia. Han, B; Zhang, R, 2022)	1.16
" In the United States, deferiprone has been approved for three times daily dosing since 2011 and has recently gained approval for twice-daily administration."	( An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes. Badawy, SM; Shah, A; Shah, R, 2023)	0.91
" Twice-daily administration provides a similar level of iron chelation as three times daily dosing with a comparable side effect profile and increased patient acceptability."	( An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes. Badawy, SM; Shah, A; Shah, R, 2023)	0.91
" In principle, iron chelators can be combined with an infinite number of dosing regimens; these involve simultaneous or sequential exposure to the chelators on the same day or alternating the drugs on different days."	( Combination chelation therapy. Aydinok, Y, 2023)	0.91

Role	Description
iron chelator	null
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
triazoles	An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.
monocarboxylic acid	An oxoacid containing a single carboxy group.
benzoic acids	Any aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group.
phenols	Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Luciferase	Photinus pyralis (common eastern firefly)	Potency	36.1254	0.0072	15.7588	89.3584	AID624030
hypoxia-inducible factor 1 alpha subunit	Homo sapiens (human)	Potency	6.0070	3.1890	29.8841	59.4836	AID1224846
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	27.1817	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
SMAD family member 2	Homo sapiens (human)	Potency	23.9145	0.1737	34.3047	61.8120	AID1346924
Fumarate hydratase	Homo sapiens (human)	Potency	37.2212	0.0030	8.7949	48.0869	AID1347053
SMAD family member 3	Homo sapiens (human)	Potency	23.9145	0.1737	34.3047	61.8120	AID1346924
TDP1 protein	Homo sapiens (human)	Potency	27.3171	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	33.4915	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	8.4621	0.0002	21.2231	8,912.5098	AID743035; AID743063
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	3.3491	0.0006	57.9133	22,387.1992	AID1259378
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	7.0901	0.0010	22.6508	76.6163	AID1224838; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	6.6824	0.0004	17.9460	75.1148	AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	2.7540	0.0123	7.9835	43.2770	AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	17.1126	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	10.7294	0.0002	14.3764	60.0339	AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	24.2589	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	2.6832	0.0008	17.5051	59.3239	AID1159527; AID1159531
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	15.6597	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	26.6011	0.3758	27.4851	61.6524	AID743217
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	25.1806	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
polyprotein	Zika virus	Potency	37.2212	0.0030	8.7949	48.0869	AID1347053
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	13.3322	0.0010	24.5048	61.6448	AID743215
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	5.9553	0.0010	19.4141	70.9645	AID743191
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	29.8493	0.0017	23.8393	78.1014	AID743083
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	23.8675	0.0016	28.0151	77.1139	AID1259385; AID1259395
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	4.2527	19.7391	45.9784	64.9432	AID1159509
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	55.5627	0.0391	47.5451	146.8240	AID1224845; AID1224896
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	25.4423	0.0003	23.4451	159.6830	AID743065; AID743066; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	1.3332	0.0006	27.2152	1,122.0200	AID743202
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	29.8493	0.0015	57.7890	15,848.9004	AID1259244
Cellular tumor antigen p53	Homo sapiens (human)	Potency	26.6032	0.0023	19.5956	74.0614	AID651631
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	29.8493	0.0015	51.7393	15,848.9004	AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Lysine-specific demethylase 6B	Homo sapiens (human)	IC50 (µMol)	3.9500	0.0160	1.6672	6.9000	AID1872471
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	36.5000	0.2000	5.6774	10.0000	AID1473741
Lysine-specific demethylase 4A	Homo sapiens (human)	IC50 (µMol)	3.7700	0.2000	2.8319	4.7600	AID1872469; AID1885301; AID1885302
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	58.4000	0.1100	7.1903	10.0000	AID1473738
Lysine-specific demethylase 5A	Homo sapiens (human)	IC50 (µMol)	5.0000	0.1300	2.3747	10.0000	AID1872470
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	3,981.0701	0.0009	1.9014	10.0000	AID1207518
Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)	IC50 (µMol)	1,000.0000	0.0003	2.2545	9.6000	AID1207552
Sodium channel protein type 5 subunit alpha	Homo sapiens (human)	IC50 (µMol)	290.3099	0.0003	3.6484	9.2000	AID1207304; AID1207336
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)	IC50 (µMol)	50.1187	1.4000	5.3500	9.3000	AID1207424
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Flavin reductase (NADPH)	Homo sapiens (human)	Kd	1.7041	0.0700	0.7968	1.7100	AID1815675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
inflammatory response to antigenic stimulus	Lysine-specific demethylase 6B	Homo sapiens (human)
chromatin remodeling	Lysine-specific demethylase 6B	Homo sapiens (human)
response to activity	Lysine-specific demethylase 6B	Homo sapiens (human)
hippocampus development	Lysine-specific demethylase 6B	Homo sapiens (human)
cell fate commitment	Lysine-specific demethylase 6B	Homo sapiens (human)
endothelial cell differentiation	Lysine-specific demethylase 6B	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Lysine-specific demethylase 6B	Homo sapiens (human)
mesodermal cell differentiation	Lysine-specific demethylase 6B	Homo sapiens (human)
cardiac muscle cell differentiation	Lysine-specific demethylase 6B	Homo sapiens (human)
response to fungicide	Lysine-specific demethylase 6B	Homo sapiens (human)
cellular response to hydrogen peroxide	Lysine-specific demethylase 6B	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Lysine-specific demethylase 6B	Homo sapiens (human)
heart development	Lysine-specific demethylase 6B	Homo sapiens (human)
regulation of gene expression	Lysine-specific demethylase 6B	Homo sapiens (human)
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
negative regulation of autophagy	Lysine-specific demethylase 4A	Homo sapiens (human)
positive regulation of gene expression	Lysine-specific demethylase 4A	Homo sapiens (human)
negative regulation of gene expression	Lysine-specific demethylase 4A	Homo sapiens (human)
cardiac muscle hypertrophy in response to stress	Lysine-specific demethylase 4A	Homo sapiens (human)
apoptotic chromosome condensation	Lysine-specific demethylase 4A	Homo sapiens (human)
response to nutrient levels	Lysine-specific demethylase 4A	Homo sapiens (human)
positive regulation of neuron differentiation	Lysine-specific demethylase 4A	Homo sapiens (human)
negative regulation of DNA-templated transcription	Lysine-specific demethylase 4A	Homo sapiens (human)
negative regulation of astrocyte differentiation	Lysine-specific demethylase 4A	Homo sapiens (human)
chromatin remodeling	Lysine-specific demethylase 4A	Homo sapiens (human)
regulation of gene expression	Lysine-specific demethylase 4A	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Lysine-specific demethylase 5A	Homo sapiens (human)
circadian regulation of gene expression	Lysine-specific demethylase 5A	Homo sapiens (human)
positive regulation of DNA-templated transcription	Lysine-specific demethylase 5A	Homo sapiens (human)
regulation of DNA-binding transcription factor activity	Lysine-specific demethylase 5A	Homo sapiens (human)
facultative heterochromatin formation	Lysine-specific demethylase 5A	Homo sapiens (human)
regulation of DNA-templated transcription	Lysine-specific demethylase 5A	Homo sapiens (human)
chromatin remodeling	Lysine-specific demethylase 5A	Homo sapiens (human)
megakaryocyte differentiation	Flavin reductase (NADPH)	Homo sapiens (human)
heme catabolic process	Flavin reductase (NADPH)	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Flavin reductase (NADPH)	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by hormone	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane depolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
immune system development	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
heart development	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
embryonic forelimb morphogenesis	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
camera-type eye development	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
positive regulation of adenylate cyclase activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
positive regulation of muscle contraction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion transport into cytosol	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
cardiac conduction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channel	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion transmembrane transport	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
cardiac muscle cell action potential involved in contraction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane depolarization during AV node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
cell communication by electrical coupling involved in cardiac conduction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
regulation of ventricular cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion import across plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
regulation of heart rate	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cardiac conduction system development	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cardiac ventricle development	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
brainstem development	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
sodium ion transport	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
positive regulation of sodium ion transport	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
response to denervation involved in regulation of muscle adaptation	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
telencephalon development	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cerebellum development	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
sodium ion transmembrane transport	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
odontogenesis of dentin-containing tooth	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
positive regulation of action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cardiac muscle contraction	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarization	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarization	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane depolarization	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cellular response to calcium ion	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cardiac muscle cell action potential involved in contraction	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of cardiac muscle cell contraction	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
atrial cardiac muscle cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
SA node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
AV node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
bundle of His cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during AV node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during SA node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during Purkinje myocyte cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during bundle of His cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
AV node cell to bundle of His cell communication	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
regulation of sodium ion transmembrane transport	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
potassium ion transport	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
protein homooligomerization	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
action potential	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Lysine-specific demethylase 6B	Homo sapiens (human)
beta-catenin binding	Lysine-specific demethylase 6B	Homo sapiens (human)
histone demethylase activity	Lysine-specific demethylase 6B	Homo sapiens (human)
metal ion binding	Lysine-specific demethylase 6B	Homo sapiens (human)
histone H3K27me2/H3K27me3 demethylase activity	Lysine-specific demethylase 6B	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Lysine-specific demethylase 6B	Homo sapiens (human)
chromatin DNA binding	Lysine-specific demethylase 6B	Homo sapiens (human)
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Lysine-specific demethylase 4A	Homo sapiens (human)
zinc ion binding	Lysine-specific demethylase 4A	Homo sapiens (human)
ubiquitin protein ligase binding	Lysine-specific demethylase 4A	Homo sapiens (human)
histone demethylase activity	Lysine-specific demethylase 4A	Homo sapiens (human)
methylated histone binding	Lysine-specific demethylase 4A	Homo sapiens (human)
histone H3K36 demethylase activity	Lysine-specific demethylase 4A	Homo sapiens (human)
histone H3K36me2/H3K36me3 demethylase activity	Lysine-specific demethylase 4A	Homo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activity	Lysine-specific demethylase 4A	Homo sapiens (human)
histone H3K9 demethylase activity	Lysine-specific demethylase 4A	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
transcription cis-regulatory region binding	Lysine-specific demethylase 5A	Homo sapiens (human)
DNA binding	Lysine-specific demethylase 5A	Homo sapiens (human)
transcription coactivator activity	Lysine-specific demethylase 5A	Homo sapiens (human)
enzyme inhibitor activity	Lysine-specific demethylase 5A	Homo sapiens (human)
protein binding	Lysine-specific demethylase 5A	Homo sapiens (human)
zinc ion binding	Lysine-specific demethylase 5A	Homo sapiens (human)
chromatin DNA binding	Lysine-specific demethylase 5A	Homo sapiens (human)
histone demethylase activity	Lysine-specific demethylase 5A	Homo sapiens (human)
histone H3K4me/H3K4me2/H3K4me3 demethylase activity	Lysine-specific demethylase 5A	Homo sapiens (human)
methylated histone binding	Lysine-specific demethylase 5A	Homo sapiens (human)
histone binding	Lysine-specific demethylase 5A	Homo sapiens (human)
biliverdin reductase (NAD(P)H) activity	Flavin reductase (NADPH)	Homo sapiens (human)
protein binding	Flavin reductase (NADPH)	Homo sapiens (human)
FMN reductase (NAD(P)H) activity	Flavin reductase (NADPH)	Homo sapiens (human)
peptidyl-cysteine S-nitrosylase activity	Flavin reductase (NADPH)	Homo sapiens (human)
riboflavin reductase (NADPH) activity	Flavin reductase (NADPH)	Homo sapiens (human)
FMN reductase (NADPH) activity	Flavin reductase (NADPH)	Homo sapiens (human)
FMN reductase (NADH) activity	Flavin reductase (NADPH)	Homo sapiens (human)
biliberdin reductase NAD+ activity	Flavin reductase (NADPH)	Homo sapiens (human)
biliverdin reductase (NADPH) activity	Flavin reductase (NADPH)	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calmodulin binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
alpha-actinin binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated sodium channel activity	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
protein binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
calmodulin binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
fibroblast growth factor binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
enzyme binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
protein kinase binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
protein domain specific binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
ankyrin binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
ubiquitin protein ligase binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
transmembrane transporter binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
nitric-oxide synthase binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potential	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
scaffold protein binding	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
A-type (transient outward) potassium channel activity	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
transmembrane transporter binding	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
metal ion binding	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Lysine-specific demethylase 6B	Homo sapiens (human)
nucleoplasm	Lysine-specific demethylase 6B	Homo sapiens (human)
MLL3/4 complex	Lysine-specific demethylase 6B	Homo sapiens (human)
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
fibrillar center	Lysine-specific demethylase 4A	Homo sapiens (human)
nucleus	Lysine-specific demethylase 4A	Homo sapiens (human)
nucleoplasm	Lysine-specific demethylase 4A	Homo sapiens (human)
cytosol	Lysine-specific demethylase 4A	Homo sapiens (human)
pericentric heterochromatin	Lysine-specific demethylase 4A	Homo sapiens (human)
nucleus	Lysine-specific demethylase 4A	Homo sapiens (human)
chromatin	Lysine-specific demethylase 4A	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
nucleus	Lysine-specific demethylase 5A	Homo sapiens (human)
nucleoplasm	Lysine-specific demethylase 5A	Homo sapiens (human)
nucleolus	Lysine-specific demethylase 5A	Homo sapiens (human)
nucleus	Lysine-specific demethylase 5A	Homo sapiens (human)
chromatin	Lysine-specific demethylase 5A	Homo sapiens (human)
cytoplasm	Flavin reductase (NADPH)	Homo sapiens (human)
nucleoplasm	Flavin reductase (NADPH)	Homo sapiens (human)
cytosol	Flavin reductase (NADPH)	Homo sapiens (human)
plasma membrane	Flavin reductase (NADPH)	Homo sapiens (human)
intracellular membrane-bounded organelle	Flavin reductase (NADPH)	Homo sapiens (human)
extracellular exosome	Flavin reductase (NADPH)	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cytoplasm	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
postsynaptic density	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
Z disc	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
dendrite	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
perikaryon	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
postsynaptic density membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
caveola	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
nucleoplasm	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
nucleolus	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
endoplasmic reticulum	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
plasma membrane	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
caveola	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
cell surface	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
intercalated disc	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
membrane	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
lateral plasma membrane	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
Z disc	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
T-tubule	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
sarcolemma	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
perinuclear region of cytoplasm	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
voltage-gated sodium channel complex	Sodium channel protein type 5 subunit alpha	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
sarcolemma	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
GABA-ergic synapse	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
postsynaptic specialization membrane	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
dendritic spine	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
neuronal cell body	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
postsynaptic membrane	Potassium voltage-gated channel subfamily D member 3	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1384631	Growth inhibition of Saccharomyces cerevisiae harboring FET3 deletion mutant at 400 uM measured for 11 hrs by HOP assay	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Yeast Chemogenomic Profiling Reveals Iron Chelation To Be the Principle Cell Inhibitory Mode of Action of Gossypol.
AID1872470	Inhibition of full-length KDM5A (1 to 1090 residues)(unknown origin) using ARTK(me3)-QTARKSTGGKAPRKQLA-GGK(biotin) as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LANCE Ultra assay	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
AID1207276	Inhibition of long-lasting type calcium current (ICaL) in HEK293 cells (alpha1C/beta2a/alpha2delta1) cells measured using IonWorks Barracuda automated patch clamp platform
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1207304	Inhibition of fast sodium current (INa) in Chinese Hamster Ovary (CHO) K1 cells transfected with human Nav1.5 measured using IonWorks Quattro automated patch clamp platform
AID561877	Toxicity in patient with mucormycosis assessed as appearance of erythematous rashes at 5 to 20 mg/kg/day, po for 14 days	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
AID1207364	Inhibition of slow delayed inward rectifying potassium current (Iks) in Chinese Hamster Ovary (CHO) cells expressing hKvLQT1/hminK measured using IonWorks Quattro automated patch clamp platform
AID1207336	Inhibition of fast sodium current (INa) in HEK293 cells transfected with human Nav1.5 measured using IonWorks Quattro automated patch clamp platform
AID460413	Inhibition of [59Fe] uptake from [59Fe]transferrin in human SK-N-MC cells assessed as at 50 uM after 3 hrs relative to untreated control	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
AID1885303	Inhibition of KDM4A in human KYSE-150 cells assessed as increase in H3K9me3 level	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Recent Advances with KDM4 Inhibitors and Potential Applications.
AID1885304	Antiproliferative activity against human KYSE-150 cells	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Recent Advances with KDM4 Inhibitors and Potential Applications.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1207490	Inhibition of rapid delayed inward rectifying potassium current (IKr) in Chinese hamster ovary (CHO) cells stable expressing hERG measured using IonWorks Barracuda automated patch clamp platform
AID561867	Toxicity in patient with mucormycosis assessed as creatinine level at 5 to 20 mg/kg/day, po for 14 days (Rvb = 1.6 mg/dl)	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
AID1384633	Growth inhibition of Saccharomyces cerevisiae harboring GEF1 deletion mutant at 400 uM measured for 11 hrs by HOP assay	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Yeast Chemogenomic Profiling Reveals Iron Chelation To Be the Principle Cell Inhibitory Mode of Action of Gossypol.
AID561875	Toxicity in patient with mucormycosis assessed as platelet count at 5 to 20 mg/kg/day, po for 14 days (Rvb = 217/uL)	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
AID1872471	Inhibition of KDM6B (1043 to end residues) (unknown origin) using ATKAARK(me3)-SAPATGGVKKPHRYRPG-GK(biotin) as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LANCE Ultra assay	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1474132	Drug concentration at steady state in human at 20 to 40 mg/kg, po QD after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1474134	Ratio of drug concentration at steady state in human at 20 to 40 mg/kg, po QD after 24 hrs to IC50 for human MRP4 overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID454622	Cytotoxicity against human MIAPaCa2 cells after 96 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2	Synthesis and antiproliferating activity of iron chelators of hydroxyamino-1,3,5-triazine family.
AID561872	Toxicity in patient with mucormycosis assessed as WBC count at 5 to 20 mg/kg/day, po for 14 days (Rvb = 8.1/uL)	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
AID1474133	Ratio of drug concentration at steady state in human at 20 to 40 mg/kg, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1207518	Inhibition of rapid delayed inward rectifying potassium current (IKr) measured using manual patch clamp assay
AID561874	Toxicity in patient with mucormycosis assessed as hemoglobin level at 5 to 20 mg/kg/day, po for 14 days (Rvb = 9 mg/dl)	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1207396	Inhibition of slow delayed inward rectifying potassium current (Iks) in Chinese Hamster Ovary (CHO) cells transfected with KCNQ1 / Kv1.7 / KvLQT1 and KCNE1/minK measured using IonWorks automated patch clamp platform
AID1815674	Binding affinity to human N-terminal His6-tagged and thrombin cleavage fused BLVRB expressed in Escherichia coli BL21 (DE3) assessed as change in gibbs free energy by isothermal titration calorimetry	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic Target.
AID1885301	Inhibition of KDM4A (unknown origin) measured by formaldehyde dehydrogenase (FDH)-coupled fluorescence assay	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Recent Advances with KDM4 Inhibitors and Potential Applications.
AID1207424	Inhibition of transient outward potassium current (Ito) current in Chinese Hamster Ovary (CHO) K1 cells expressing human Kv4.3 measured using IonWorks Quattro automated patch clamp platform
AID1815675	Binding affinity to human N-terminal His6-tagged and thrombin cleavage fused BLVRB expressed in Escherichia coli BL21 (DE3) assessed as dissociation constant by isothermal titration calorimetry	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic Target.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1815672	Binding affinity to human N-terminal His6-tagged and thrombin cleavage fused BLVRB expressed in Escherichia coli BL21 (DE3) assessed as change in enthalpy by isothermal titration calorimetry	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic Target.
AID419505	Volume of distribution at steady state in human at 130 mg administered 90 mins infusion	2009	Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14	In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID561869	Toxicity in patient with mucormycosis assessed as aspartate transaminase level at 5 to 20 mg/kg/day, po for 14 days (Rvb = 27 U/l)	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID561878	Toxicity in patient with mucormycosis assessed as alanine transaminase level at 5 to 20 mg/kg/day, po for 14 days (Rvb = 21 U/l)	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID454623	Cytotoxicity against human foreskin fibroblasts after 96 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2	Synthesis and antiproliferating activity of iron chelators of hydroxyamino-1,3,5-triazine family.
AID561876	Toxicity in patient with mucormycosis assessed as glucose level at 5 to 20 mg/kg/day, po for 14 days (Rvb = 131 mg/dl)	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625276	FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI	2011	Drug discovery today, Aug, Volume: 16, Issue:15-16	FDA-approved drug labeling for the study of drug-induced liver injury.
AID454621	Cytotoxicity against human MDA-MB-231 cells after 96 hrs by MTT assay	2010	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2	Synthesis and antiproliferating activity of iron chelators of hydroxyamino-1,3,5-triazine family.
AID1885305	Antiproliferative activity against human HL-60 cells	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Recent Advances with KDM4 Inhibitors and Potential Applications.
AID460407	Partition coefficient, log P by shake flask method	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1829741	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID561868	Toxicity in patient with mucormycosis assessed as blood urea nitrogen level at 5 to 20 mg/kg/day, po for 14 days (Rvb = 34 mg/dl)	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
AID460410	Toxicity in human SK-N-MC cells by MTT method	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1829742	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay
AID1207552	Inhibition of long-lasting type calcium current (hICa) in Chinese Hamster Ovary (CHO) cells expressing hCav1.2 measured using IonWorks Quattro automated patch clamp platform
AID1384635	Growth inhibition of wild type Saccharomyces cerevisiae BY4743 at 100 uM measured for 15 hrs in presence of Fe2+	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Yeast Chemogenomic Profiling Reveals Iron Chelation To Be the Principle Cell Inhibitory Mode of Action of Gossypol.
AID1815673	Binding affinity to human N-terminal His6-tagged and thrombin cleavage fused BLVRB expressed in Escherichia coli BL21 (DE3) assessed as change in entropy by isothermal titration calorimetry	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Repositioning Food and Drug Administration-Approved Drugs for Inhibiting Biliverdin IXβ Reductase B as a Novel Thrombocytopenia Therapeutic Target.
AID1207458	Inhibition of rapid delayed inward rectifying potassium current (IKr) in Chinese hamster ovary (CHO) K1 cells stably expressing hERG measured using IonWorks Quattro automated patch clamp platform
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1885302	Inhibition of KDM4A (unknown origin) measured by LANCEUltra assay	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Recent Advances with KDM4 Inhibitors and Potential Applications.
AID561873	Toxicity in patient with mucormycosis assessed as absolute neutrophil count at 5 to 20 mg/kg/day, po for 14 days (Rvb = 5.2/uL)	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
AID1474131	AUC in human at 20 to 40 mg/kg, po QD after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1872469	Inhibition of KDM4A (1 to 359 residues) (unknown origin) using ARTKQTARK(me3)-STGGKAPRKQLA-GGK(biotin) peptide as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LANCE Ultra assay	2022	European journal of medicinal chemistry, Mar-05, Volume: 231	Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
AID460409	Toxicity in MDCK cells by MTT method	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID561870	Toxicity in patient with mucormycosis assessed as alkaline phosphatase level at 5 to 20 mg/kg/day, po for 14 days (Rvb = 126 U/l)	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
AID561871	Toxicity in patient with mucormycosis assessed as total bilirubin level at 5 to 20 mg/kg/day, po for 14 days (Rvb = 0.8 mg/dl)	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1347170	Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149	Furin counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347153	Confirmatory screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347171	Orthogonal mCherry assay for qRT-PCR qHTS of selected Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164	384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347152	Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161	Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347150	Optimization screen NINDS AMC qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168	HepG2 cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163	384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347172	Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167	Vero cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169	Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347155	Optimization screen NINDS Rhodamine qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158	ZIKV-mCherry secondary qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	157 (19.53)	29.6817
2010's	522 (64.93)	24.3611
2020's	125 (15.55)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	136 (16.35%)	5.53%
Reviews	126 (15.14%)	6.00%
Case Studies	111 (13.34%)	4.05%
Observational	20 (2.40%)	0.25%
Other	439 (52.76%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (93)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Other Patients With Rare Chronic Anemia and Transfusional Iron Overload [NCT00303329]	Phase 2	184 participants (Actual)	Interventional	2004-03-31	Completed
A Study to Provide Expanded Access of (Exjade®) Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload From Blood Transfusions Who Cannot Adequately be Treated With Other Locally Approved Iron Chelators [NCT00235391]	Phase 3	1,683 participants (Actual)	Interventional	2005-10-31	Completed
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients With Iron Overload [NCT02435212]	Phase 2	224 participants (Actual)	Interventional	2015-10-21	Active, not recruiting
Open-label, Multicenter, Single Arm, Phase II Study Assessing Treatment Patient Preference for New Deferasirox Formulation (Film-coated Tablet) Compared to the Reference Deferasirox Dispersible Tablet Formulation [NCT02993224]	Phase 2	148 participants (Actual)	Interventional	2017-07-27	Completed
A Phase II Study of Deferasirox in Patients With Myelodysplastic Syndromes Who Are Anemic With Iron Overload [NCT02943668]	Phase 2	2 participants (Actual)	Interventional	2017-03-02	Terminated(stopped due to Terminated due to low accrual)
Multicenter Prospective Observational Study of the Outcome of Patients With Acute Myeloblastic Leukemia (AML) and Myelodysplastic Syndrome (MDS) Receiving Iron Chelation Therapy (Exjade) After Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) [NCT03659084]		150 participants (Anticipated)	Observational	2016-04-30	Recruiting
Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload Patients With β-Thalassemia and Intermediate Thalassemia in Bandarabbas [NCT01369719]		138 participants (Actual)	Interventional	2010-02-28	Completed
A PHASE II STUDY OF Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS) [NCT02038816]	Phase 2	1 participants (Actual)	Interventional	2014-03-31	Terminated(stopped due to accrual too slow, insufficient patients)
A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets [NCT03372083]	Phase 4	44 participants (Actual)	Interventional	2018-01-16	Completed
Open-Label Single-Arm Pilot Study of Deferasirox (Exjade®) in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload [NCT01335035]	Phase 4	30 participants (Actual)	Interventional	2008-12-31	Completed
Effects of Iron Loading and Iron Chelation Therapy on Innate Immunity During Human Endotoxemia [NCT01349699]		30 participants (Actual)	Interventional	2010-02-28	Completed
A Phase II, Open Label Clinical Trial Exploring the Safety and the Efficacy of Oral Deferasirox in Patients Newly Diagnosed With Porphyria Cutanea Tarda (PCT) and Non-transfusion Iron Overload [NCT01284946]	Phase 2	45 participants (Anticipated)	Interventional	2011-01-31	Recruiting
An Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-Risk and INT-1 Myelodysplastic Patients [NCT00117507]	Phase 4	24 participants (Actual)	Interventional	2005-09-30	Completed
The Use of the Calcium Channel Blocker Amlodipine as an Adjuvant Treatment to Iron Chelation for the Prevention of Iron Overload Cardiomyopathy in Patients With Thalassemia [NCT02474420]		60 participants (Anticipated)	Interventional	2015-06-30	Recruiting
Low Dose Iron Chelation as TReatment of Oxidative Damage in Patients With Sickle Cell Disease: the TROS Study [NCT05392101]	Phase 2	12 participants (Actual)	Interventional	2021-07-20	Completed
A Multicenter, Open-label, Single Arm, Interventional Phase IV Study, to Evaluate the Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia [NCT02069886]	Phase 4	0 participants (Actual)	Interventional	2014-12-31	Withdrawn
The Shuttle Effect : Combination Therapy With Deferiprone and Deferasirox in Transfusion-dependent Thalassemia Patients. [NCT02198508]		13 participants (Actual)	Interventional	2007-07-31	Completed
Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox) [NCT02233504]	Early Phase 1	25 participants (Anticipated)	Interventional	2014-08-31	Completed
Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda [NCT00599326]	Phase 3	10 participants (Actual)	Interventional	2008-01-31	Completed
1 Year, Open-label Multicenter Evaluation of Efficacy, Safety of Deferasirox in Patients MDS, Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. [NCT01250951]	Phase 4	111 participants (Actual)	Interventional	2009-12-31	Completed
A Multi-Center, Open-Label, Two-Period Cross-Over, Patient-Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Iron Chelating Activity of DST-0509 (Deferasirox) Tablets in Thalassemia Patients With Inadequate Response to Standard Chelat [NCT03637556]	Phase 2	25 participants (Actual)	Interventional	2019-08-20	Completed
Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS [NCT03920657]	Phase 2	11 participants (Actual)	Interventional	2019-10-04	Terminated(stopped due to enrollment failed)
Open-label, Multicenter, Single Arm, Phase III Study to Collect Additional Safety and Efficacy Data With Deferasirox Film-coated Tablets in Patients Completing Study CICL670F2201 [NCT02720536]	Phase 3	53 participants (Actual)	Interventional	2016-08-16	Completed
A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload. [NCT01326845]	Phase 4	12 participants (Actual)	Interventional	2011-12-31	Terminated(stopped due to The trial was terminated due to insufficient enrollment.)
A 5-year Open Label, Non-comparative Extension to a Randomized, Open-label, Phase IIa Study to Evaluate Safety, Tolerability and the Effects on Liver Iron Concentration of Repeated Doses of 10 and 20 mg/kg/Day of Deferasirox in Comparison With 40 mg/kg/Da [NCT01033747]	Phase 2/Phase 3	70 participants (Actual)	Interventional	2003-02-28	Completed
A Single-arm, Open-label Study of the Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food [NCT00845871]	Phase 4	65 participants (Actual)	Interventional	2009-05-31	Completed
An Open Label Trial Evaluating Cardiac T2* in Beta-thalassemia Patients on Deferasirox (ICL670) Treatment for 18 Months [NCT00447694]	Phase 2	30 participants (Actual)	Interventional	2006-02-28	Completed
An Iron Balance Study Comparing Deferasirox, Deferoxamine and the Combination of Both Drugs [NCT00738413]	Phase 1/Phase 2	6 participants (Anticipated)	Interventional	2008-08-31	Recruiting
A Randomized, Open-label, Multi-center, Phase II Study to Evaluate the Safety and Efficacy of Deferasirox (ICL670) 20 mg/kg/Day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients With Iron Overload From Repeated Blood Transfusions [NCT00110617]	Phase 2	212 participants (Actual)	Interventional	2005-05-31	Completed
A Multicenter, Randomized, Open-label Phase II Trial Evaluating Deferasirox Compared With Deferoxamine in Patients With Cardiac Iron Overload Due to Chronic Blood Transfusions [NCT00600938]	Phase 2	197 participants (Actual)	Interventional	2007-11-30	Completed
A Study of Magnetic Resonance Imaging Assessment of Cardiac and Liver Iron Load in Patients With Haemoglobinopathies, Myelodysplastic Syndromes (MDS) or Other Anaemias Treated With Exjade® (Deferasirox) (The MILE Study) [NCT00673608]	Phase 4	118 participants (Actual)	Interventional	2007-11-30	Completed
A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/d) in Patients Three to Six Months After Allogeneic Hematopoietic Cell Transplantation in Whom Iron Overload is Present [NCT00654589]	Phase 4	75 participants (Actual)	Interventional	2008-02-29	Completed
A Randomized, Open Label, Phase II Study on Safety and Efficacy of Long Term Treatment of ICL670 Relative to Deferoxamine in Sickle Cell Disease Patients With Transfusional Hemosiderosis [NCT00067080]	Phase 2	195 participants (Actual)	Interventional	2003-05-31	Completed
A Phase I/II Open Label, Dose Escalation Trial and a Six Month Extension to Explore the Safety and Efficacy of ICL670 in Patients With Iron Overload Resulting From Hereditary Hemochromatosis. [NCT00395629]	Phase 1/Phase 2	49 participants (Actual)	Interventional	2006-08-31	Completed
Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload [NCT00560820]	Phase 1	11 participants (Actual)	Interventional	2007-09-30	Completed
International Sentinel Site Surveillance of Patients With Transfusional Hemosiderosis Treated With Deferasirox in Actual Practice Setting [NCT01394029]		120 participants (Actual)	Observational	2011-07-31	Completed
Study of The Therapeutic Benefits of Al-hijamah in Children With Beta Thalassemia Major [NCT02761395]		60 participants (Anticipated)	Interventional	2015-11-30	Recruiting
A Phase II, Multicenter, Open-label, Randomized Two-year Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis. [NCT03203850]	Phase 2	45 participants (Actual)	Interventional	2018-01-11	Completed
A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity [NCT01044186]	Phase 2	30 participants (Actual)	Interventional	2003-06-30	Completed
A 4-year Extension to a Phase II a Multicenter Study Evaluating Long-term Safety, Tolerability, Pharmacokinetics and Effects on Liver Iron Concentration of Repeated Doses of 10 mg/kg/Day of Deferasirox in Pediatric Patients With Transfusion Dependent β-th [NCT00390858]	Phase 2	40 participants (Actual)	Interventional	2003-09-30	Completed
An Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-risk and INT-1, Myelodysplastic Patients Using Serum Ferritin Monitoring [NCT00110266]	Phase 2	176 participants (Actual)	Interventional	2005-07-25	Completed
Renal Function Among Thalassemia Patients Treated by a Oral Chelator Deferasirox [NCT01905774]		36 participants (Actual)	Observational	2011-03-31	Completed
A Prospective Single Arm Study to Assess the Efficacy and Safety of Deferasirox 20 mg/kg BID in Transfusion Dependent Thalassemia Patients Inadequately Responding to Current Treatment With Doses > 35mg/kg QD (Once a Day). [NCT01948817]	Phase 2	0 participants (Actual)	Interventional	2014-02-28	Withdrawn
Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload [NCT00564941]	Phase 4	309 participants (Anticipated)	Interventional	2007-12-31	Completed
An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670)in β-thalassemia Patients With Transfusional Iron Overload [NCT00171210]	Phase 3	506 participants (Actual)	Interventional	2004-10-31	Completed
A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate Efficacy and Safety of Deferasirox in Non-transfusion-dependent Thalassemia Patients With Iron Overload [NCT00873041]	Phase 2	166 participants (Actual)	Interventional	2008-11-30	Completed
Phase II, Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Patients With Severe Cardiac Iron Overload Due to Chronic Blood Transfusion (HYP [NCT01254227]	Phase 2	60 participants (Actual)	Interventional	2011-01-31	Completed
A One Year Open Label, Non-comparative Extension to a Randomized, Multicenter, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration (LIC) of Repeated Doses of 5-30mg/kg/Day ICL670 Relative to D [NCT01090323]	Phase 2	185 participants (Actual)	Interventional	2004-07-31	Completed
Phase 2 Study of Deferasirox-calcium-vitamin D3 to Treat Postmenopausal Osteoporosis (PMOP) [NCT02854722]	Phase 2	10 participants (Anticipated)	Interventional	2018-01-15	Recruiting
Multicenter, Open Label, Prospective Study to Evaluate the Efficacy and Safety of Deferasirox 30 mg/kg/Day for 52 Weeks, in Transfusion-dependent Beta-thalassemic Patients With Cardiac MRI T2* < 20 Msec [NCT00879242]	Phase 2	20 participants (Actual)	Interventional	2009-02-28	Completed
A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial of Deferasirox in Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) and Transfusional Iron Overload [NCT00940602]	Phase 2	225 participants (Actual)	Interventional	2010-03-22	Completed
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study [NCT00419770]	Phase 2	20 participants (Actual)	Interventional	2007-10-31	Completed
Early Treatment With Deferasirox (Exjade®) in Low Risk MDS - a Prospective Multicentre Single-arm Single-stage Phase II Study - [NCT01058369]	Phase 2	2 participants (Actual)	Interventional	2010-04-30	Terminated(stopped due to Insufficient patient recruitment (only 2 patients))
An Open-label, One-sequence Cross-over Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam in Healthy Volunteers [NCT00427505]	Phase 1	22 participants	Interventional	2006-07-31	Completed
Open Label, Multicenter Study to Evaluate Safety/Tolerability and Efficacy of Deferasirox (ICL670) in Myelodysplastic Syndrome Patients With Chronic Transfusional Hemosiderosis. [NCT00469560]	Phase 3	158 participants (Actual)	Interventional	2007-06-30	Completed
A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 in Patients Diagnosed With Low and INT-1 Risk Myelodysplastic Syndrome (MDS) and Transfusion-dependent Iron Overload [NCT00481143]	Phase 4	63 participants (Actual)	Interventional	2007-05-31	Completed
Identification of Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients Undergoing a Hematopoietic Stem Cell Transplant (HSCT) [NCT04423237]		39 participants (Anticipated)	Observational	2020-09-30	Recruiting
A Multicenter Open Label Phase II Study to Evaluate the Safety and Efficacy of Deferasirox in Combination With Deferoxamine Followed by Transitioning to Deferasirox Monotherapy in β-thalassemia Patients With Severe Cardiac Iron Overload [NCT01459718]	Phase 2	32 participants (Actual)	Interventional	2011-01-31	Terminated(stopped due to The study terminated due to low enrollment.)
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox [NCT00466063]		108 participants (Actual)	Observational	2007-05-31	Completed
A Study of Efficacy and Safety of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis [NCT00171171]	Phase 3	252 participants (Actual)	Interventional	2004-05-31	Completed
A One Year, Open-label, Single-arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/Day) in Patients Diagnosed With Transfusion-dependent Iron Overload [NCT00171821]	Phase 3	1,784 participants (Actual)	Interventional	2005-04-30	Completed
A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload [NCT01511848]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2012-02-29	Not yet recruiting
A 48-week, Open-label, 2-arm, Parallel-group, Randomized Exploratory Study to Assess Liver Iron Concentration Measured by FerriScan® (R2) Magnetic Resonance Imaging in B-thalassemia Subjects Administered SPD602 (SSP-004184AQ) or Exjade® (Deferasirox) for [NCT01927913]	Phase 2	0 participants (Actual)	Interventional	2014-11-20	Withdrawn(stopped due to This study was withdrawn until the evaluation of the nonclinical rat findings is complete.)
A Randomized, Comparative, Open Label Phase III Trial on Efficacy & Safety of Long-term Treatment With ICL670 Compared to Deferoxamine in Beta-thalassemia Patients With Transfusional Hemosiderosis [NCT00061750]	Phase 3	595 participants (Actual)	Interventional	2003-05-31	Completed
Phase II Study of Safety & Efficacy of Deferasirox Given for 1 Year in Patients With Chronic Anemias and Transfusional Hemosiderosis Unable to be Treated With Deferoxamine [NCT00061763]	Phase 2	175 participants (Actual)	Interventional	2003-05-31	Completed
Pilot Pharmacokinetic Study In Patients With Inadequate Response To Deferasirox (Exjade) [NCT00749515]	Phase 4	15 participants (Actual)	Interventional	2008-03-31	Completed
Deferasirox Treatment and Labile Plasma Iron in Iron Overloaded Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation [NCT01159067]	Phase 2	1 participants (Actual)	Interventional	2010-07-31	Terminated(stopped due to Low enrollment)
Multicentre, Randomised, Open Label, Non-inferiority Trial to Evaluate the Efficacy and Safety of Deferiprone Compared to Deferasirox in Patients Aged From 1 Month to Less Than 18 Years Affected by Transfusion Dependent Haemoglobinopathies [NCT01825512]	Phase 3	435 participants (Actual)	Interventional	2014-03-17	Completed
1-year Extension to CICL670A2402 an Open-label, Multi-center Trial of the Efficacy and Safety of Long-term Treatment With Deferasirox (10 to 20 mg/kg/Day) in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2- Year Duration) [NCT00171301]	Phase 4	233 participants (Actual)	Interventional	2005-06-30	Completed
A Phase I, Single Center, Open-label, One-sequence Cross-over Study to Investigate the Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers [NCT00419172]	Phase 1	22 participants (Anticipated)	Interventional	2007-01-31	Completed
A Phase IV , Multicenter ,Open Label ,Non Comparative ,Investigator Initiated Study , Evaluating the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load [NCT00452660]	Phase 4	21 participants (Actual)	Interventional	2007-05-31	Completed
The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (NASH) - a Prospective Open Label Phase I/II Trial [NCT01278056]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2010-03-31	Completed
Phase I-II Study of Association of Deferasirox, Vitamin D and Azacytidine as Treatment of High Risk MDS (IPSS Int-2 and High) [NCT01718366]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2013-02-28	Active, not recruiting
Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload [NCT01273766]	Phase 2	16 participants (Actual)	Interventional	2011-01-31	Completed
Open-label Study of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Undergoing Treatment Programs in Comparison With Control Group [NCT01818726]	Phase 4	15 participants (Actual)	Interventional	2014-06-23	Terminated(stopped due to Failure to meet the schedule of patient recruitment)
A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy in Hematological Centers in Belgium Using Gene Expressing Profiling From Baseline Bon [NCT02663752]	Phase 2	1 participants (Actual)	Interventional	2016-05-30	Terminated
Clinical Importance of Treating Iron Overload in Sickle Cell Disease [NCT00981370]	Phase 3	1 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to 1 consented patient never started on study drug, lost to follow up)
A Multi-Center, Open-label, Non Comparative, Phase II Trial on Efficacy and Safety of ICL670 Given for 1 Year With Dose Adjustments Based on Serum Ferritin in Patients With Chronic Anemia and Transfusional Hemosiderosis Including an Additional 1 Year Exte [NCT00631163]	Phase 2	102 participants (Actual)	Interventional	2007-10-31	Completed
Safety of Deferasirox (ICL670) and Deferoxamine (Desferal or DFO) Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload [NCT00901199]	Phase 2	22 participants (Actual)	Interventional	2007-09-30	Completed
An Open-label, Single-dose, Parallel-group Study to Assess the Pharmacokinetics of 20 mg/kg Oral Deferasirox in Patients With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function [NCT00432627]	Phase 1	24 participants (Actual)	Interventional	2006-12-31	Completed
An Open-label, Phase II, Randomized, Pilot Study to Assess the Effect in Term of Erythroid Improvement of Deferasirox Combined With Erythropoietin Compared to Erythropoietin Alone in Patients With low-and Int-1-risk Myelodysplastic Syndrome. [NCT01868477]	Phase 2	28 participants (Actual)	Interventional	2014-01-28	Completed
A Phase II Study Examining the Use of Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed Acute Myelogenous Leukemia (AML) in Elderly Patients [NCT02341495]	Phase 2	4 participants (Actual)	Interventional	2013-02-28	Terminated(stopped due to Study was terminated early due to low patient accrual.)
Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload [NCT00379483]	Phase 2	66 participants (Actual)	Interventional	2002-07-31	Completed
A 2-year, Multi-center, Phase II, Open-label, Fixed-dose, Randomized Comparative Trial of Azacitidine, With or Without Deferasirox in Patients With Higher Risk Myelodysplastic Syndromes [NCT02159040]	Phase 2	1 participants (Actual)	Interventional	2014-09-11	Terminated
Phase 1 Study of Deferasirox in Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens [NCT02413021]	Phase 1	40 participants (Anticipated)	Interventional	2016-05-31	Not yet recruiting
An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old [NCT01724138]	Phase 4	0 participants (Actual)	Interventional	2013-06-30	Withdrawn
Deferasirox Versus Venesection in Patients With Hemochromatosis and for Treatment of Transfusional Siderosis in Myelodysplastic Syndrome: Diagnostics and New Biomarkers. [NCT01892644]	Phase 2	50 participants (Actual)	Interventional	2013-05-31	Terminated(stopped due to Failure to recruit patients with hemochromatosis to the Deferasirox arm)
Open-Label Single-Arm Pilot Study of Deferasirox (Exjade®) in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload [NCT00602446]	Phase 2	4 participants (Actual)	Interventional	2007-08-31	Terminated(stopped due to Due to slow accrual of patients)
A Phase II, Multi-center, Single-arm, Prospective Study to Evaluate the Safety and Efficacy of Deferasirox in Beta-thalassemia Major Patients After Hematopoietic Stem Cell Transplantation. [NCT01610297]	Phase 4	27 participants (Actual)	Interventional	2013-09-30	Completed
Pilot Study of Deferasirox and Deferiprone Combination Oral Chelation for Individuals With Transfusion Dependent Thalassemia and High Iron Burden [NCT01709032]	Phase 1/Phase 2	9 participants (Actual)	Interventional	2012-09-30	Completed
An Open Label, Multi-center, Efficacy and Safety Study of Deferasirox in Iron Overloaded Patients With Non-transfusion Dependent Thalassemia [NCT01709838]	Phase 4	134 participants (Actual)	Interventional	2012-12-06	Completed
Phase II Trial Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk (MDS) Myelodysplastic Syndrome Resistant or Relapsing After ESA Agents (LODEFI) [NCT03387475]	Phase 2	39 participants (Anticipated)	Interventional	2018-02-20	Recruiting
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet) [NCT02125877]	Phase 2	173 participants (Actual)	Interventional	2014-07-08	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00110266 (12) [back to overview]	Treatment Compliance to Deferasirox
NCT00110266 (12) [back to overview]	Trough Plasma Deferasirox Concentration
NCT00110266 (12) [back to overview]	Number of Participants Reporting Adverse Events
NCT00110266 (12) [back to overview]	Change in Labile Plasma Iron (LPI)
NCT00110266 (12) [back to overview]	Total Iron Levels
NCT00110266 (12) [back to overview]	Change in Serum Ferritin From Baseline to Weeks 13, 25, 37 and 53
NCT00110266 (12) [back to overview]	Directly Chelatable Iron (DCI)
NCT00110266 (12) [back to overview]	Frequency of Hematologic Improvement During the Study
NCT00110266 (12) [back to overview]	Serum Transferrin Levels
NCT00110266 (12) [back to overview]	Transfusion Requirements
NCT00110266 (12) [back to overview]	Transferrin Saturation
NCT00110266 (12) [back to overview]	The Prevalence of Hereditary Hemochromatosis Gene (HFE) Gene Mutations
NCT00110617 (4) [back to overview]	Absolute Change in Serum Ferritin After Start of Treatment With Deferasirox (ICL670) to Week 104
NCT00110617 (4) [back to overview]	The Number of Participants With Adverse Events (AEs) in the First 24 Weeks of Treatment
NCT00110617 (4) [back to overview]	Absolute Change in Serum Ferritin After Start of Treatment With Deferasirox (ICL670) to Week 24 and to Week 52
NCT00110617 (4) [back to overview]	Absolute Change in Serum Ferritin From Baseline to Week 24
NCT00117507 (8) [back to overview]	Number of Participants With Adverse Events and Serious Adverse Events
NCT00117507 (8) [back to overview]	Labile Plasma Iron (LPI)
NCT00117507 (8) [back to overview]	Absolute Change in Urinary Hepcidin
NCT00117507 (8) [back to overview]	Absolute Change in Transferrin Saturation
NCT00117507 (8) [back to overview]	Absolute Change in Serum Ferritin From Baseline to Week 52
NCT00117507 (8) [back to overview]	Absolute Change in Liver Iron Concentration (LIC) From Baseline to End of Study
NCT00117507 (8) [back to overview]	To Evaluate Change in Transfusion Requirements
NCT00117507 (8) [back to overview]	Absolute Change in Serum Erythropoietin
NCT00171210 (12) [back to overview]	Relative Change in Liver Iron Content From Start of ICL670 Treatment to End of Study Measured by Biopsy
NCT00171210 (12) [back to overview]	Absolute Change in Liver Iron Content From Start of ICL670 Treatment to End of Study Measured by Biopsy
NCT00171210 (12) [back to overview]	Absolute Change in Liver Iron Content From Start of ICL670 Treatment to End of Study Measured by SQUID
NCT00171210 (12) [back to overview]	Change in Surrogate Marker: Serum Iron From Start of Treatment With ICL670 to End of Study
NCT00171210 (12) [back to overview]	Change in Surrogate Marker: Serum Transferrin From Start of Treatment With ICL670 to End of Study
NCT00171210 (12) [back to overview]	Change in Surrogate Marker: Transferrin Saturation From Start of Treatment With ICL670 to End of Study
NCT00171210 (12) [back to overview]	Change of Total Body Iron Excretion Rate (TBIE) From Start of ICL670 Treatment to the End of Study
NCT00171210 (12) [back to overview]	Long-term Effect of ICL670 on Hepatic Iron Stores Measured by Means of Liver Iron Content (LIC) as Assessed by Liver Biopsy
NCT00171210 (12) [back to overview]	Long-term Effect of ICL670 on Hepatic Iron Stores Measured by Means of Liver Iron Content (LIC) as Assessed by SQUID
NCT00171210 (12) [back to overview]	Long-term Effect of Treatment With ICL670 on the Changes in Serum Ferritin Levels From Start of ICL670 Treatment to End of Study
NCT00171210 (12) [back to overview]	Relative Change in Liver Iron Content From Start of ICL670 Treatment to End of Study as Measured by SQUID
NCT00171210 (12) [back to overview]	Long Term Safety and Tolerability Profile of ICL670 Based on the Number of Participants Who Experienced Any Adverse Event
NCT00171301 (4) [back to overview]	Percentage of Participants With Treatment Success From Core Baseline (BL) to Extension End of Study, by Baseline LIC Level and Age
NCT00171301 (4) [back to overview]	Absolute Change in Serum Ferritin Level Measured From Core Study Baseline (BL) to End of Extension Study
NCT00171301 (4) [back to overview]	Absolute Change in Liver Iron Concentration (LIC)Measured by Liver MRI or Liver Biopsy From Core Study Baseline (BL) to End of Extension Study, by LIC Category
NCT00171301 (4) [back to overview]	Absolute Change in Serum Ferritin Level for All Participants Measured From Core Study Baseline (BL) to End of Extension Study, by Baseline Liver Iron Content (LIC)
NCT00235391 (2) [back to overview]	Safety Profile of Deferasirox Based Upon Drug Administration and Reporting of Serious Adverse Events
NCT00235391 (2) [back to overview]	The Change in Serum Ferritin Values From Baseline Through Completion of the Study
NCT00303329 (4) [back to overview]	The Change in Liver Iron Content (LIC) as Assessed by Liver Biopsy at Baseline to the End of the Study
NCT00303329 (4) [back to overview]	The Absolute Change in Serum Ferritin (μg/L) Levels From Baseline to the End of the Study
NCT00303329 (4) [back to overview]	The Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) or Deaths
NCT00303329 (4) [back to overview]	The Absolute Change in Liver Iron Content (LIC) as Assessed by Superconducting Quantum Interference Device (SQUID) From Baseline to End of Study
NCT00390858 (4) [back to overview]	Relative Change in Serum Ferritin Level
NCT00390858 (4) [back to overview]	Participants With Adverse Events by Primary System Organ Class (SOC)
NCT00390858 (4) [back to overview]	Total Body Iron Elimination (TBIE) Rate (mg/kg/Day)
NCT00390858 (4) [back to overview]	Change in Liver Iron Concentration (LIC)
NCT00395629 (2) [back to overview]	Absolute Change of Serum Ferritin From Baseline to the End of Extension, by Dose Cohort (Extension Per-protocol Population)
NCT00395629 (2) [back to overview]	Trough Concentrations of Deferasirox (ICL670), by Dose Cohort (Per-protocol Population)
NCT00419770 (1) [back to overview]	Total Adverse Events
NCT00447694 (4) [back to overview]	Serum Ferritin and Changes From Baseline in Serum Ferritin During Study
NCT00447694 (4) [back to overview]	Magnetic Resonance Imaging (MRI) T2* and Absolute Change From Baseline in MRI T2*
NCT00447694 (4) [back to overview]	Left Ventricular Ejection Fraction (LVEF) and Change in Left Ventricular Ejection Fraction From Baseline to 101 Weeks
NCT00447694 (4) [back to overview]	Change From Baseline in Liver Iron Concentration (LIC) Was Measured by MRI R2 From Absolute Change From Baseline to 101 Weeks
NCT00599326 (2) [back to overview]	Number of Participants Showing Reduction or Elimination of Skin Blistering
NCT00599326 (2) [back to overview]	Number of Participants Showing Decrease in Ferritin and Urinary Porphyrin Level
NCT00600938 (21) [back to overview]	Extension Study: Change in Serum Ferritin From Baseline by Month
NCT00600938 (21) [back to overview]	Extension Study: The Cardiac Iron Concentration From T2* Values
NCT00600938 (21) [back to overview]	Core Study: Single and Repeated Dose Pharmacokinetics of Deferasirox, Maximum Plasma Concentration (Cmax)
NCT00600938 (21) [back to overview]	Extension Study: Change in Liver Iron Concentration (LIC) From Baseline at Month 24
NCT00600938 (21) [back to overview]	Core Study: Single and Repeated Dose Pharmacokinetics of Deferasirox, Maximum Plasma Concentration (Tmax)
NCT00600938 (21) [back to overview]	Core Study: Cardiac Function After 6 and 12 Months of Treatment With Deferasirox vs. Deferoxamine, by Change in Left Ventricular Mass Indices (LVMI)
NCT00600938 (21) [back to overview]	Core Study: Cardiac Function After 6 and 12 Months Treatment With Deferasirox vs. Deferoxamine, by Change in Left Ventricular End Systolic Volume Indices (LVESVI)
NCT00600938 (21) [back to overview]	Core Study: Core Study: Cardiac Function After 6 and 12 Months of Treatment With Deferasirox vs. Deferoxamine, by Change in Left Ventricular End Diastolic Volume Indices (LVEDVI)
NCT00600938 (21) [back to overview]	Core Study: Single and Repeated Dose Pharmacokinetics of Deferasirox, Time Points of Concentration Data
NCT00600938 (21) [back to overview]	Extension Study: Cardiac Function From Baseline to Month 24 by Change in Left Ventricular Ejection Fraction (LVEF)
NCT00600938 (21) [back to overview]	Extension Study: Cardiac Function From Baseline to Month 24 by Change in Left Ventricular End Diastolic Volume Indices (LVEDVI)
NCT00600938 (21) [back to overview]	Extension Study: Cardiac Function From Baseline to Month 24 by Change in Left Ventricular End Systolic Volume Indices (LVESVI)
NCT00600938 (21) [back to overview]	Extension Study: Cardiac Function From Baseline to Month 24 by Change in Left Ventricular Mass Indices (LVMI)
NCT00600938 (21) [back to overview]	Extension Study: Change From Baseline in Myocardial T2* After 24 Months Treatment
NCT00600938 (21) [back to overview]	Core Study: Safety and Tolerability of Deferasirox vs Deferoxamine Over the 12 Months Treatment Period.
NCT00600938 (21) [back to overview]	Core Study: Cardiac Function After 12 Months of Treatment With Deferasirox vs. Deferoxamine, by Change in Left Ventricular Ejection Fraction (LVEF)
NCT00600938 (21) [back to overview]	Core Study: Cardiac Function After 6 Months of Treatment With Deferasirox vs. Deferoxamine, by Change in Left Ventricular Ejection Fraction (LVEF)
NCT00600938 (21) [back to overview]	Core Study: Cardiac Function and the Proportion of Patients Dropping Out Due to Cardiac Dysfunction After Treatment With Deferasirox vs. Deferoxamine
NCT00600938 (21) [back to overview]	Core Study: Change From Baseline in Myocardial T2* (Magnetic Resonance T2-star (T2*) Technique for the Measurement of Tissue Iron) After 12 Months Treatment
NCT00600938 (21) [back to overview]	Core Study: Change From Baseline in Myocardial T2* After 6 Months Treatment
NCT00600938 (21) [back to overview]	Core Study: Single and Repeated Dose Pharmacokinetics of Deferasirox, Area Under the Plasma Concentration-time Curve for a Dosing Interval (AUCtau)
NCT00602446 (2) [back to overview]	Number of Patients Not Completing Treatment
NCT00602446 (2) [back to overview]	Reduction in Liver Iron Concentration After Study Drug
NCT00631163 (9) [back to overview]	Absolute Change From Baseline in Liver Iron Concentration (LIC) to Year 1
NCT00631163 (9) [back to overview]	Correlation of LIC and Serum Ferritin at Core and Extension Study
NCT00631163 (9) [back to overview]	Absolute Change From Baseline in Liver Iron Concentration (LIC) in Japanese Subgroup
NCT00631163 (9) [back to overview]	Absolute Serum Ferritin Levels Over 2 Years
NCT00631163 (9) [back to overview]	Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Event of Special Interest (AESI), Discontinuation and Interruption
NCT00631163 (9) [back to overview]	Absolute Change From Baseline in Serum Ferritin Levels to Year 2
NCT00631163 (9) [back to overview]	Absolute Change From Baseline in Liver Iron Concentration (LIC) to End of Year 2
NCT00631163 (9) [back to overview]	Number of Participants With Clinically Significant Ophthalmological Abnormalities
NCT00631163 (9) [back to overview]	Total Body Iron Elimination Rate (TBIE), Iron Intake, Iron Excretion/Iron Intake and Chelation Efficiency After 2 Years
NCT00749515 (6) [back to overview]	Number of Participants With Polymorphisms in Genes Known to be, or Potentially Involved, in Deferasirox Disposition
NCT00749515 (6) [back to overview]	Half-Life of Deferasirox
NCT00749515 (6) [back to overview]	Area Under the Curve of Deferasirox After a Dose of 35 mg/kg
NCT00749515 (6) [back to overview]	Clearance/Bioavailability of Deferasirox in Patients With Poor Response to Deferasirox Compared to Patients With Good Response After a Dose of 35 mg/kg
NCT00749515 (6) [back to overview]	Volume of Distribution/Bioavailability of Deferasirox After a Dose of 35 mg/kg
NCT00749515 (6) [back to overview]	Volume of Distribution/Bioavailability of Deferasirox After a Dose of 35 mg/kg
NCT00845871 (4) [back to overview]	Trough Plasma Concentration of Deferasirox at Week 8, Week 12 and Week 16
NCT00845871 (4) [back to overview]	Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation and Interruption
NCT00845871 (4) [back to overview]	Change From Baseline in Serum Ferritin at Week 16
NCT00845871 (4) [back to overview]	Percentage of Participants With Differing Palatability Scores at Week 8 and Week 12
NCT00873041 (20) [back to overview]	Extension Study: Absolute Change in Serum Ferritin From Baseline to Eighth Quarter
NCT00873041 (20) [back to overview]	Extension Study: Change From Baseline in Hemoglobin at Month 24
NCT00873041 (20) [back to overview]	Extension Study: Change From Baseline in Transferrin Saturation at Month 24
NCT00873041 (20) [back to overview]	Extension Study: Change in Liver Iron Concentration (LIC) From Baseline at Month 24
NCT00873041 (20) [back to overview]	Extension Study: Correlation Between Serum Ferritin and LIC (Liver Iron Concentration)
NCT00873041 (20) [back to overview]	Extension Study: Percentage of Participants Reaching a Liver Iron Concentration (LIC) < 5 mg Fe/g dw From Core Baseline to End of Extension Study
NCT00873041 (20) [back to overview]	Core Study: Change in Liver Iron Concentration (LIC) From Baseline At Week 24 and Week 52 in Patients With Dose Increases After Week 24
NCT00873041 (20) [back to overview]	Core Study: Correlation Between Serum Ferritin and LIC (Liver Iron Concentration)
NCT00873041 (20) [back to overview]	Core Study: Percentage of Participants With Adverse Events Graded Mild, Moderate and Severe
NCT00873041 (20) [back to overview]	Core Study: Percentage of Participants With Notable Abnormal Post-baseline Laboratory Results
NCT00873041 (20) [back to overview]	Core Study: Percentage of Participants With Notably Abnormal Post-baseline Diastolic Blood Pressure
NCT00873041 (20) [back to overview]	Core Study: Percentage of Participants With Notably Abnormal Post-baseline Pulse Rate
NCT00873041 (20) [back to overview]	Core Study: Percentage of Participants With Notably Abnormal Post-baseline Systolic Blood Pressure
NCT00873041 (20) [back to overview]	Core Study: Change From Baseline in Hemoglobin at Month 12
NCT00873041 (20) [back to overview]	Core Study: Change From Baseline in Transferrin Saturation at Month 12
NCT00873041 (20) [back to overview]	Core Study: Change in Liver Iron Concentration (LIC) From Baseline to Week 24
NCT00873041 (20) [back to overview]	Core Study: Change in Liver Iron Concentration (LIC) From Baseline to Week 52
NCT00873041 (20) [back to overview]	Core Study: Change in Liver Iron Concentration (LIC) in Placebo Patients From Baseline to Week 52
NCT00873041 (20) [back to overview]	Core Study: Change in Serum Ferritin Between Baseline and Fourth Quarter
NCT00873041 (20) [back to overview]	Core Study: Change in Serum Ferritin Between Baseline and Second Quarter
NCT00901199 (2) [back to overview]	Efficacy of Combined Treatment With Deferasirox and Deferoxamine Over 12 Months
NCT00901199 (2) [back to overview]	Change in Serum Creatinine During 12 Months Combined Chelation Therapy
NCT00940602 (16) [back to overview]	Percentage of Participants With Significant Renal Dysfunction
NCT00940602 (16) [back to overview]	Time to at Least a 10% Increase From Baseline in Left Ventricular End-diastolic Internal (LVIDD) at Two Consecutive Assessments at Least Two Weeks Apart
NCT00940602 (16) [back to overview]	Percentage of Participants With Newly Occurring Moderate or Severe Neutropenia
NCT00940602 (16) [back to overview]	Percentage of Participants With Newly Occurring Severe Thrombocytopenia
NCT00940602 (16) [back to overview]	Percentage of Participants With Worsening Glucose Metabolism Compared to Baseline
NCT00940602 (16) [back to overview]	All Collected Deaths
NCT00940602 (16) [back to overview]	Total Number of Infections Requiring Intravenous Antimicrobials
NCT00940602 (16) [back to overview]	Time to Study Drug Discontinuation Due to an AE or Laboratory Abnormality
NCT00940602 (16) [back to overview]	Time to First Occurrence of Serum Ferritin Level >2 Times the Baseline Value at Two Consecutive Assessments (at Least Two Weeks Apart)
NCT00940602 (16) [back to overview]	Time to Disease Progression
NCT00940602 (16) [back to overview]	Time to at Least a 10% Increase From Baseline in Left Ventricular Internal Systolic Diameter (LVISD) at Two Consecutive Assessments at Least Two Weeks Apart
NCT00940602 (16) [back to overview]	Percentage of Participants With Newly Occurring Hypothyroidism Compared to Baseline
NCT00940602 (16) [back to overview]	Percentage of Participants With Major Gastrointestinal Bleeding
NCT00940602 (16) [back to overview]	Percentage of Participants With Hematologic Improvement (HI) in Terms of Erythroid Response
NCT00940602 (16) [back to overview]	Event-free Survival
NCT00940602 (16) [back to overview]	Overall Survival
NCT01033747 (2) [back to overview]	Relative Change in Serum Ferritin From Baseline to 3.5 Years
NCT01033747 (2) [back to overview]	The Relative Change From Baseline in Liver Iron Content (LIC) After Prolonged Use of Deferasirox
NCT01090323 (2) [back to overview]	Number of Participants With Adverse Events After Start of ICL670
NCT01090323 (2) [back to overview]	Change in Serum Ferritin From Start of ICL670 to End of Study
NCT01159067 (2) [back to overview]	Number of Patients With Elevated Labile Plasma Iron (LPI) Above Threshold (0.5 Umol/L)
NCT01159067 (2) [back to overview]	Number of Patients With Serum Ferritin Level Lower Than 1500 ng/mL After Treatment
NCT01254227 (7) [back to overview]	Percentage of Participants With T2*>=10 ms and at Least 10% Relative Increase From Baseline at Month 6, 12, 18 and 24
NCT01254227 (7) [back to overview]	Time to Achieve From Baseline (FAS) of at Least 10% at Month 24
NCT01254227 (7) [back to overview]	Cardiac Iron Concentration Levels From Baseline and at Month 6, 12, 18 and 24
NCT01254227 (7) [back to overview]	Change in Cardiac Iron Content From Baseline to Month 6,18 and 24
NCT01254227 (7) [back to overview]	Change in Right Ventricular Ejection Fraction (RVEF) From Baseline to Month 6, 12, 18 and 24
NCT01254227 (7) [back to overview]	Change in Left Ventricular Ejection Fraction (LVEF) From Baseline to Month 6, 12, 18 and 24
NCT01254227 (7) [back to overview]	Change in Cardiac Iron Content From Baseline to Month 12
NCT01273766 (3) [back to overview]	Changes in Mean Neutrophil Values (as Measured by Lab) for Arm 1 (Other Arms Were Used for Calibration Only)
NCT01273766 (3) [back to overview]	Need for Hospitalization, Ventilator Support, Exchange Transfusion/Apheresis or Treatment With Antifungals or Antibiotics
NCT01273766 (3) [back to overview]	Cumulative Incidence of Documented Bacterial, Fungal, and Viral Infections
NCT01459718 (8) [back to overview]	Left Ventricular Ejection Fraction (LVEF)
NCT01459718 (8) [back to overview]	Time to Response
NCT01459718 (8) [back to overview]	Number of Patients Achieving a Complete Response (CR)
NCT01459718 (8) [back to overview]	Number of Patients Achieving a Partial Response (PR)
NCT01459718 (8) [back to overview]	Number of Patients With Stable Disease (SD)
NCT01459718 (8) [back to overview]	Change From Baseline in Cardiac Iron Overload of Patients in Intensive Iron Chelation Therapy Consisting of Deferasirox-DFO and After Transition to Deferasirox Monotherapy
NCT01459718 (8) [back to overview]	Change From Baseline in Liver Iron Concentration (LIC)
NCT01459718 (8) [back to overview]	Correlation Between Change From Baseline in Serum Ferritin and LIC Levels
NCT01610297 (5) [back to overview]	The Percentage of Patients Reaching Serum Ferritin Levels Lower Than 500 μg/L
NCT01610297 (5) [back to overview]	Change in Serum Ferritin Level.
NCT01610297 (5) [back to overview]	Change in the Further Parameters of Iron Overload (Cardiac Iron Concentration by Magnetic Resonance Imaging (MRI Examination)
NCT01610297 (5) [back to overview]	Change in the Further Parameters of Iron Overload (Liver Iron Concentration by Magnetic Resonance Imaging (MRI Examination)
NCT01610297 (5) [back to overview]	Number of Participants With Adverse Events, Serious Adverse Events and Deaths as a Measure of Safety and Tolerability
NCT01709032 (2) [back to overview]	Number of Participants With Improvement in Cardiac T2* MRI
NCT01709032 (2) [back to overview]	Number of Participants With Improvement in Liver Iron Concentration
NCT01709838 (15) [back to overview]	Absolute Change in Health-related Outcomes Using Medical Outcomes Study Form 36 (SF-36v2)
NCT01709838 (15) [back to overview]	Absolute Change in Liver Iron Content (LIC) at 52 Weeks From Baseline
NCT01709838 (15) [back to overview]	Absolute Change in Serum Ferritin From Baseline After 52 Weeks
NCT01709838 (15) [back to overview]	Percentage of Participants With Baseline LIC>15 Achieving LIC<5 mg Fe/g dw
NCT01709838 (15) [back to overview]	PK Parameters: AUCtau
NCT01709838 (15) [back to overview]	PK Parameters: Cmax
NCT01709838 (15) [back to overview]	PK Parameters: Tmax
NCT01709838 (15) [back to overview]	Time From Target LIC of 3 mg Fe/g dw to the First LIC ≥5 mg Fe/g dw in the Follow up Period
NCT01709838 (15) [back to overview]	Time to Achieving LIC <5 mg Fe/g dw
NCT01709838 (15) [back to overview]	Absolute Change in Health-related Outcomes Using the Pediatric Quality of Life Questionnaire (PedsQL™)
NCT01709838 (15) [back to overview]	Absolute Change in LIC From Baseline After 52 Weeks of Treatment by Underlying Non-transfusion Dependent Thalassemia (NTDT) Syndrome
NCT01709838 (15) [back to overview]	Correlation Analysis for Absolute Change in LIC and Serum Ferritin at Week 24 and EOS (Week 260 + 30 Days Follow-up)
NCT01709838 (15) [back to overview]	Absolute Change in LIC From Baseline Over Time
NCT01709838 (15) [back to overview]	Plasma Pharmacokinetics (PK) Deferasirox Concentrations
NCT01709838 (15) [back to overview]	Serum Ferritin (SF) vs LIC at Baseline and EOS (Week 260 + 30 Days Follow-up)
NCT01818726 (3) [back to overview]	Change in Serum Ferritin Values
NCT01818726 (3) [back to overview]	Change in Serum Total Iron-binding Capacity (TIBC)
NCT01818726 (3) [back to overview]	Change in Transferrin Saturation With Iron (TSI) Values
NCT01825512 (4) [back to overview]	Liver MRI
NCT01825512 (4) [back to overview]	Cardiac MRI T2*
NCT01825512 (4) [back to overview]	Ferritin Level
NCT01825512 (4) [back to overview]	Percentage of Successfully Chelated Patients
NCT01868477 (15) [back to overview]	Absolute Change in Serum Ferritin up to 24 Weeks for EPO+DFX at 12 Weeks Arm (Full Analysis Set)
NCT01868477 (15) [back to overview]	Absolute Change in Serum Ferritin up to 24 Weeks for Erythropoietin Alpha Arm (Full Analysis Set)
NCT01868477 (15) [back to overview]	Summary of Hematologic Improvement in Patients Randomized to EPO+DFX and EPO Alone, Within 24 Weeks of Treatment (Full Analysis Set)
NCT01868477 (15) [back to overview]	Absolute Change in Hemoglobin (Hb) From Baseline for EPO+DFX at 12 Weeks Arm (Full Analysis Set)
NCT01868477 (15) [back to overview]	Absolute Change in Serum Ferritin up to 24 Weeks for Deferasirox + Erythropoietin Alpha Arm (Full Analysis Set)
NCT01868477 (15) [back to overview]	Absolute Change From Baseline to Post-baseline Value for Hemoglobin(g/dL)(Full Analysis Set)
NCT01868477 (15) [back to overview]	Absolute Change in Hemoglobin Values up to 24 Weeks
NCT01868477 (15) [back to overview]	Difference in Percentage of Patients Achieving Erythroid Response Within 12 Weeks, by Treatment Group (Full Analysis Set)
NCT01868477 (15) [back to overview]	Summary of Erythroid Response in Participants Randomized to EPO Alone at Baseline and Switched to EPO+DFX After 12 Weeks of Treatment (Full Analysis Set)
NCT01868477 (15) [back to overview]	Summary of Erythroid Response Within 24 Weeks in Participants Randomized to EPO at Baseline and Not Switched to EPO+DFX After 12 Weeks of Treatment (Full Analysis Set)
NCT01868477 (15) [back to overview]	Absolute Change in Hemoglobin (Hb) From Baseline for Deferasirox + Erythropoietin Alpha Arm (Full Analysis Set)
NCT01868477 (15) [back to overview]	Absolute Change in Hemoglobin (Hb) From Baseline for EPO+DFX at 12 Weeks Arm (Full Analysis Set)
NCT01868477 (15) [back to overview]	Absolute Change in Hemoglobin (Hb) From Baseline for Erythropoietin Alpha Arm (Full Analysis Set)
NCT01868477 (15) [back to overview]	Absolute Change in Platelets and Neutrophil Levels up to 24 Weeks
NCT01868477 (15) [back to overview]	Absolute Change in Serum Ferritin up to 24 Weeks for Deferasirox + Erythropoietin Alpha Arm (Full Analysis Set)
NCT02125877 (12) [back to overview]	Weekly Average of Daily Scores of the Gastrointestinal (GI) Symptom Diary
NCT02125877 (12) [back to overview]	Weekly Dose Violation Rate
NCT02125877 (12) [back to overview]	Time to Reach the Maximum Plasma Concentration After Drug Administration (Tmax)
NCT02125877 (12) [back to overview]	Palatability Questionnaire Score
NCT02125877 (12) [back to overview]	Overall Safety as Measured by Frequency of Adverse Events
NCT02125877 (12) [back to overview]	Overall Safety as Measured by Changes in Laboratory Values From Baseline
NCT02125877 (12) [back to overview]	Observed Maximum Plasma Concentration Following Drug Administration (Cmax)
NCT02125877 (12) [back to overview]	Number of Participants With Weekly Average Compliance of Medication Consumption
NCT02125877 (12) [back to overview]	Frequency of Selected Gastro-intestinal (GI) Adverse Events
NCT02125877 (12) [back to overview]	Dererasirox Plasma Concentration
NCT02125877 (12) [back to overview]	Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)
NCT02125877 (12) [back to overview]	Mean Domain Scores of the Modified Satisfaction With Iron Chelation Therapy (Modified SICT)
NCT02720536 (10) [back to overview]	Change From Baseline Serum Creatinine (Umol/L) at Month 6 and Month 12
NCT02720536 (10) [back to overview]	Percentage Relative Change From Baseline of Serum Ferritin (%) at Month 6 and 12
NCT02720536 (10) [back to overview]	Overview of Number of Participants With Adverse Events
NCT02720536 (10) [back to overview]	Change From Baseline Platelets (10^9 Cells/L) at Month 6 and Month 12
NCT02720536 (10) [back to overview]	Change From Baseline Red Blood Cells (RBC) (10^12 Cells/L) at Month 6 and Month 12
NCT02720536 (10) [back to overview]	Change From Baseline of Serum Ferritin Level (ug/L) at Month 6 and 12
NCT02720536 (10) [back to overview]	Change From Baseline Creatinine Clearance (mL/Min) at Month 6 and Month 12
NCT02720536 (10) [back to overview]	Change From Baseline Aspartate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) (U/L) at Month 6 and Month 12
NCT02720536 (10) [back to overview]	Change From Baseline Alanine Aminotransferase/Serum Glutamic Pyruvic Transaminase (ALT/SGPT) (U/L) at Month 6 and Month 12
NCT02720536 (10) [back to overview]	Change From Baseline White Blood Cells (WBC) (10^9 Cells/L) at Month 6 and Month 12
NCT02943668 (4) [back to overview]	Proportion of Patients That Achieve Erythroid Hematologic Improvement.
NCT02943668 (4) [back to overview]	Proportion of Patients Who Achieve Granulocyte or Platelet Hematologic Improvement
NCT02943668 (4) [back to overview]	Change in Red Blood Cell (RBC) Transfusion Requirements
NCT02943668 (4) [back to overview]	Change in Serum Ferritin Levels
NCT02993224 (10) [back to overview]	Change From Baseline in Gastrointestinal (GI) Symptom Score Based on GI Questionnaire
NCT02993224 (10) [back to overview]	Change From Baseline in Preference Domain Score of Modified Satisfaction With Iron Chelation (mSICT) Questionnaire
NCT02993224 (10) [back to overview]	Change From Baseline in Serum Ferritin Levels
NCT02993224 (10) [back to overview]	Change Over Time in Palatability Score of Palatability Questionnaire
NCT02993224 (10) [back to overview]	Change Over Time in Aftertaste Score of Palatability Questionnaire
NCT02993224 (10) [back to overview]	Number of Participants Preferring Deferasirox DT or Previous Iron Chelation Therapy at Week 4 and Week 24 Based on Preference Questionnaire (Item 2)
NCT02993224 (10) [back to overview]	Change From Baseline in Concerns Domain Score of Modified Satisfaction With Iron Chelation (mSICT) Questionnaire
NCT02993224 (10) [back to overview]	Change From Baseline in Adherence Domain Score of Modified Satisfaction With Iron Chelation (mSICT) Questionnaire
NCT02993224 (10) [back to overview]	Percentage of Consumed Tablet Counts During Deferasirox DT and Deferasirox FCT Treatment Periods
NCT02993224 (10) [back to overview]	Number of Participants Selecting Each Reason for Treatment Preference as Assessed by the Preference Questionnaire at Week 28 and Week 48
NCT03372083 (29) [back to overview]	Number of Participants With Worst Post-baseline Values in Selected Chemistry Parameters
NCT03372083 (29) [back to overview]	Number of Participants With GI Bowel Movements Item Scoring in Participants Pre-treated With Deferasirox
NCT03372083 (29) [back to overview]	Number of Participants With GI Bowel Movements Item Scoring in Chelation Naive Participants
NCT03372083 (29) [back to overview]	Absolute Change From Baseline in Body Temperature (°C)
NCT03372083 (29) [back to overview]	Number of Participants With Notable Changes in ECG Values From Baseline
NCT03372083 (29) [back to overview]	Number of Participants With Clinically Significant Ocular Assessments Changes From Baseline
NCT03372083 (29) [back to overview]	Number of Participants With Clinically Significant Auditory Assessments Changes From Baseline
NCT03372083 (29) [back to overview]	Modified Satisfaction With Iron Chelation Therapy (Modified SICT) in Chelation Naive Participants: Mean Change From Baseline in Concerns
NCT03372083 (29) [back to overview]	Modified Satisfaction With Iron Chelation Therapy (Modified SICT) in Chelation Naive Participants: Number of Participants With Type of Medicine Child Like Scoring
NCT03372083 (29) [back to overview]	Modified Satisfaction With Iron Chelation Therapy (Modified SICT) in Participants Pre-treated With Deferasirox: Mean Change From Baseline in Adherence
NCT03372083 (29) [back to overview]	GI Symptom Score in Participants Pre-treated With Deferasirox
NCT03372083 (29) [back to overview]	Palatability Score in Participants Pre-treated With Deferasirox
NCT03372083 (29) [back to overview]	Modified Satisfaction With Iron Chelation Therapy (Modified SICT) in Chelation Naive Participants: Number of Participants With Rank Based on Child's Preference Scoring
NCT03372083 (29) [back to overview]	GI Symptom Score in Chelation Naive Participants
NCT03372083 (29) [back to overview]	Adverse Events Profile
NCT03372083 (29) [back to overview]	Absolute Change From Baseline in Systolic and Diastolic Blood Pressures (mmHg)
NCT03372083 (29) [back to overview]	Absolute Change From Baseline in Serum Ferritin (SF)
NCT03372083 (29) [back to overview]	Modified Satisfaction With Iron Chelation Therapy (Modified SICT) in Chelation Naive Participants: Number of Participants With Reasons Child Preferred Crushed Medicine Scoring
NCT03372083 (29) [back to overview]	Absolute Change From Baseline in Body Weight (kg)
NCT03372083 (29) [back to overview]	Modified Satisfaction With Iron Chelation Therapy (Modified SICT) in Participants Pre-treated With Deferasirox: Mean Change From Baseline in Concerns
NCT03372083 (29) [back to overview]	Modified Satisfaction With Iron Chelation Therapy (Modified SICT) in Chelation Naive Participants: Mean Change From Baseline in Adherence
NCT03372083 (29) [back to overview]	Number of Chelation Naive Participants With Palatability After Taste Item Scoring
NCT03372083 (29) [back to overview]	Number of Participants With Selected Gastrointestinal Disorders up to 24 Weeks
NCT03372083 (29) [back to overview]	Palatability Score in Chelation Naive Participants
NCT03372083 (29) [back to overview]	Modified SICT in Participants Pre-treated With Deferasirox: Number of Participants With Rank Based on Child's Preference Scoring
NCT03372083 (29) [back to overview]	Modified SICT in Participants Pre-treated With Deferasirox: Number of Participants With Reasons Child Preferred Crushed Medicine Scoring
NCT03372083 (29) [back to overview]	Modified SICT in Participants Pre-treated With Deferasirox: Number of Participants With Type of Medicine Child Like Scoring
NCT03372083 (29) [back to overview]	Number of Participants Pre-treated With Deferasirox With Palatability After Taste Item Scoring
NCT03372083 (29) [back to overview]	Absolute Change From Baseline in Pulse Rate (Bpm)

Treatment Compliance to Deferasirox

Treatment compliance was assessed using records of study medication used, dosages administered, and intervals between visits during the study. Drug accountability was noted by the field monitor during site visits and at the completion of the trial. Participants were asked to return all unused medication at monthly visits. (NCT00110266)
Timeframe: up to 1 year

Intervention	participants (Number)
	20 to < 40 %	40 - < 60 %	60 - < 80 %	80 - < 100 %	100 - < 120 %	≥ 120 %
Deferasirox	2	1	4	89	65	12

Intervention	μmol/L (Median)
	Week 13	Week 25	Week 37	Week 49
Deferasirox	21.200	26.700	25.200	30.700

Intervention	LPI Unit (Median)
	Baseline	Week 13	Week 25	Week 37	Week 49
Deferasirox	0.30	-0.10	-0.20	-0.30	-0.45

Intervention	Participants (Count of Participants)
	Screening	Week 1 through 13	Week 14 through 26	Week 27 through 39	Week 40 through 52
Deferasirox	163	136	119	98	72

Intervention	Participants (Count of Participants)
	C282Y72456542		H63D72456542	S65C72456542
	Negative	Positive Heterozygous
Deferasirox	85
Deferasirox	9
Deferasirox	70
Deferasirox	24
Deferasirox	92
Deferasirox	2

Intervention	participants (Number)
	Headache	Sickle cell anaemia with crisis	Diarrhoea	Vomiting	Pyrexia	Nausea	Abdominal pain	Upper respiratory tract infection	Rash	Cough	Constipation	Pain in Extremity	Back Pain	Chest Pain	Oropharyngeal pain	Pruritus	Abdominal pain upper	Nasal congestion	Urinary tract infection	Arthralgia	Nasopharyngitis	Insomnia	Dizziness	Injection site pain
Deferasirox (ICL670)	30	30	30	21	19	20	16	10	14	10	11	10	8	7	7	7	8	6	9	7	4	3	2	0
Deferoxamine (DFO) Then ICL670	17	8	5	9	9	4	6	9	3	7	2	3	4	5	5	5	3	4	0	1	3	3	3	3

Intervention	mg/mL (Least Squares Mean)
	24 weeks from ICL670 treatment start (n=111,47)	52 weeks from ICL670 treatment start (n=113,40)
Deferasirox (ICL670)	-146.7	-487.3
Deferoxamine (DFO) Then ICL670	-204.7	-545.7

Intervention	mg/mL (Least Squares Mean)
Deferasirox (ICL670)	-173.2
Deferoxamine (DFO) Then ICL670	-868.7

Intervention	percentage of transferrin saturation (Mean)
	Baseline	Week 52/EOS (Change from baseline)
Deferasirox	59.3	8.6

Intervention	blood tranfusions (Mean)
	Number of Transfusions per Patient	Number of Units of Blood Transfused per Patient
Deferasirox	15.5	34.0

Intervention	percentage of participants (Mean)
	Core Baseline LIC 1-<7 mg Fe/g dw (n=20, 2)	Core Baseline LIC 7-<10 mg Fe/g dw (n=18, 8)	Core Baseline LIC ≥10 mg Fe/g dw (n=124, 61)
Deferasirox (16 Years or Older)	100	50.0	73.8
Deferasirox (Between 2 <16 Years)	75.0	72.2	76.6

Intervention	µg/L (Mean)
Deferasirox (Between 2 <16 Years)	-1432.51
Deferasirox (16 Years or Older)	-1791.91

Intervention	mg Fe/g dw (Mean)
	Core Baseline LIC 1-<7 mg Fe/g dw (n=12, 0)	Core Baseline LIC ≥7 mg Fe/g dw (n=107, 41)
Deferasirox (16 Years or Older)	NA	-8.39
Deferasirox (Between 2 <16 Years)	-1.32	-9.03

Intervention	µg/L (Mean)
	Core Baseline LIC 1-<7 mg Fe/g dw (n=12)	Core Baseline LIC ≥ 7 mg Fe/g dw (n=151)
Deferasirox (All Participants)	-369.83	-1619.31

Intervention	Participants (Number)
	Number of deaths	Non-fatal SAEs	AEs leading to discontinuation	AEs leading dose adjustment/temporary interruption
≥ 65 Years	0	2	2	2
12 to < 16 Years	1	27	10	28
16 to < 50 Years	4	129	75	209
2 to < 6 Years	0	10	4	15
50 to < 65 Years	0	4	5	11
6 to < 12 Years	0	22	5	31

Intervention	Participants (Number)
	Improvement	No Change	Worsening
≥ 65 Years	2	3	1
12 to < 16 Years	26	87	55
16 to < 50 Years	206	570	341
2 to < 6 Years	17	63	16
50 to < 65 Years	4	31	7
6 to < 12 Years	27	106	63

Intervention	μg/L (Mean)
	Baseline	End of Study	Absolute Change
Rare Anemias Patients	3268.8	2896.0	-382.2
β-thalassemia Patients	4320.6	3708.2	-612.4

Intervention	Participants (Number)
	Adverse Events	Serious Adverse Events	Deaths
Rare Anemias Patients	99	50	12
β-thalassemia Patients	85	36	2

Intervention	participants (Number)
	Patients with at least one Adverse Event (AE)	General disorders & administration site conditions	Respiratory, thoracic & mediastinal disorders	Gastrointestinal disorders	Infections & infestations	Musculoskeletal & connective tissue disorders	Investigations	Nervous system disorders	Skin & subcutaneous tissue disorders	Injury, poisoning & procedural complications	Ear & labyrinth disorders	Metabolism & nutrition disorders	Eye disorders	Renal & urinary disorders	Hepatobiliary disorders	Reproductive system & breast disorders	Cardiac disorders	Blood & lymphatic system disorders	Psychiatric disorders	Immune system disorders	Surgical & medical procedures	Endocrine disorders	Vascular disorders	Congenital, familial & genetic disorders
Adolescents ( ≧12 Years)	20	20	17	17	17	15	10	13	8	8	8	10	9	6	7	8	5	5	4	2	3	1	2	0
Children (<12 Years)	20	19	19	18	18	12	13	9	12	11	9	6	6	3	1	0	1	1	2	0	0	1	0	1

Intervention	mg/kg/Day (Mean)
	Core Baseline TBIE (n=19, 20)	End of Extension TBIE (n=11,14)
Adolescents ( ≧12 Years)	0.4083	0.4286
Children (<12 Years)	0.4292	0.4939

Intervention	mg Fe/g dw (Mean)
	Core Baseline LIC (n = 20, 20)	End of Extension LIC (n=19, 20)	Change from Baseline LIC (n=19, 20)
Adolescents ( ≧12 Years)	5.73	4.66	-1.10
Children (<12 Years)	6.25	5.46	-0.9

deferasirox

Description

Cross-References

Synonyms (114)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (4)

Protein Targets (44)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (258)

Molecular Functions (106)

Ceullar Components (60)

Bioassays (125)

Research

Studies (804)

Market Indicators

Research Demand Index: 77.80

Study Types

Clinical Trials (93)

Trial Overview

Trial Outcomes

Treatment Compliance to Deferasirox

Trough Plasma Deferasirox Concentration

Number of Participants Reporting Adverse Events

Change in Labile Plasma Iron (LPI)

Total Iron Levels

Change in Serum Ferritin From Baseline to Weeks 13, 25, 37 and 53

Directly Chelatable Iron (DCI)

Frequency of Hematologic Improvement During the Study

Serum Transferrin Levels

Transfusion Requirements

Transferrin Saturation

The Prevalence of Hereditary Hemochromatosis Gene (HFE) Gene Mutations

Absolute Change in Serum Ferritin After Start of Treatment With Deferasirox (ICL670) to Week 104

The Number of Participants With Adverse Events (AEs) in the First 24 Weeks of Treatment

Absolute Change in Serum Ferritin After Start of Treatment With Deferasirox (ICL670) to Week 24 and to Week 52

Absolute Change in Serum Ferritin From Baseline to Week 24

Number of Participants With Adverse Events and Serious Adverse Events

Labile Plasma Iron (LPI)

Absolute Change in Urinary Hepcidin

Absolute Change in Transferrin Saturation

Absolute Change in Serum Ferritin From Baseline to Week 52

Absolute Change in Liver Iron Concentration (LIC) From Baseline to End of Study

To Evaluate Change in Transfusion Requirements

Absolute Change in Serum Erythropoietin

Relative Change in Liver Iron Content From Start of ICL670 Treatment to End of Study Measured by Biopsy

Absolute Change in Liver Iron Content From Start of ICL670 Treatment to End of Study Measured by Biopsy

Absolute Change in Liver Iron Content From Start of ICL670 Treatment to End of Study Measured by SQUID

Change in Surrogate Marker: Serum Iron From Start of Treatment With ICL670 to End of Study

Change in Surrogate Marker: Serum Transferrin From Start of Treatment With ICL670 to End of Study

Change in Surrogate Marker: Transferrin Saturation From Start of Treatment With ICL670 to End of Study

Change of Total Body Iron Excretion Rate (TBIE) From Start of ICL670 Treatment to the End of Study

Long-term Effect of ICL670 on Hepatic Iron Stores Measured by Means of Liver Iron Content (LIC) as Assessed by Liver Biopsy

Long-term Effect of ICL670 on Hepatic Iron Stores Measured by Means of Liver Iron Content (LIC) as Assessed by SQUID

Long-term Effect of Treatment With ICL670 on the Changes in Serum Ferritin Levels From Start of ICL670 Treatment to End of Study

Relative Change in Liver Iron Content From Start of ICL670 Treatment to End of Study as Measured by SQUID

Long Term Safety and Tolerability Profile of ICL670 Based on the Number of Participants Who Experienced Any Adverse Event

Percentage of Participants With Treatment Success From Core Baseline (BL) to Extension End of Study, by Baseline LIC Level and Age

Absolute Change in Serum Ferritin Level Measured From Core Study Baseline (BL) to End of Extension Study

Absolute Change in Liver Iron Concentration (LIC)Measured by Liver MRI or Liver Biopsy From Core Study Baseline (BL) to End of Extension Study, by LIC Category

Absolute Change in Serum Ferritin Level for All Participants Measured From Core Study Baseline (BL) to End of Extension Study, by Baseline Liver Iron Content (LIC)

Safety Profile of Deferasirox Based Upon Drug Administration and Reporting of Serious Adverse Events

The Change in Serum Ferritin Values From Baseline Through Completion of the Study

The Change in Liver Iron Content (LIC) as Assessed by Liver Biopsy at Baseline to the End of the Study

The Absolute Change in Serum Ferritin (μg/L) Levels From Baseline to the End of the Study

The Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) or Deaths

The Absolute Change in Liver Iron Content (LIC) as Assessed by Superconducting Quantum Interference Device (SQUID) From Baseline to End of Study

Relative Change in Serum Ferritin Level

Participants With Adverse Events by Primary System Organ Class (SOC)

Total Body Iron Elimination (TBIE) Rate (mg/kg/Day)

Intervention	µg/L (Mean)
Deferasirox (ICL670) 5 mg/kg/Day	-389.1
Deferasirox (ICL670) 10 mg/kg/Day	-610.5
Deferasirox (ICL670) 15 mg/kg/Day	-571.6

Intervention	µmol/L (Mean)
	Week 4 (n=10,14,17)	Week 8 (n=10,12,17)	Week 12 (n=10,12,13)	Week 16 (n=10,11,11)	Week 20 (n=9,10,8)	Week 24 (n=10,9,6)
Deferasirox (ICL670) 10 mg/kg/Day	19.62	23.88	28.71	21.62	26.47	21.32
Deferasirox (ICL670) 15 mg/kg/Day	30.48	27.06	23.39	21.80	27.58	26.83
Deferasirox (ICL670) 5 mg/kg/Day	9.63	8.86	10.58	12.38	11.72	14.62

Intervention	μg/L (Mean)
	Baseline	Week 25	Week 25 Absolute change from baseline	Week 49	Week 49 Absolute change from baseline	Week 77	Week 77 Absolute change from baseline
Deferasirox	4343.75	4280.77	-62.98	3759.29	-593.36	3179.81	-882.74

Intervention	participants (Number)
	Decrease in ferritin level	Decrease in urinary porphyrin level
Deferasirox	8	6

Intervention	ug/L (Mean)
	Month 6 (n=72,28,38,0)	Month 12 (n=70,29,40,1)	Month 18 (n=66,24,39,1)	Month 24 (n=59,24,30,0)
Extension: DFO to DFO	-1307.14	-1877.00	-2426.92	-2724.00
Extension: DFO to ICL	-1054.87	-1223.73	-1494.82	-1513.23
Extension: ICL to DFO	NA	-498.00	-1067.00	NA
Extension: ICL to ICL	-626.10	-988.46	-1962.14	-2239.03

Intervention	mg Fe/g dw (Mean)
	Month 6 (n=71,26,40,1)	Month 12 (n=66,29,41,1)	Month 18 (n=68,26,39,1)	Month 24 (n=63,25,33,1)
Extension: DFO to DFO	-0.12	-0.12	-0.45	-0.69
Extension: DFO to ICL	-0.08	-0.14	-0.20	-0.34
Extension: ICL to DFO	0	-0.77	-0.24	-0.52
Extension: ICL to ICL	-0.12	-0.38	-0.47	-0.70

Intervention	mg Fe/g dw (Mean)
	Month 6 (n=71,26,38,1)	Month 12 (n=69,29,40,1)	Month 18 (n=70,23,38,1)	Month 24 (n=60,24,33,1)
Extension: DFO to DFO	-12.66	-19.44	-26.09	-26.02
Extension: DFO to ICL	-6.30	-7.98	-10.87	-10.96
Extension: ICL to DFO	-3.80	-3.90	-2.90	-3.20
Extension: ICL to ICL	-4.56	-10.22	-12.26	-15.74

Intervention	gram/m^2 (Mean)
	Change from Baseline at 6 Month (n= 85, 73)	Change from Baseline at 12 Month/EOS (n= 91, 81)
Core: Deferasirox (ICL). For Extension Labeled as ICL to ICL	1.01	4.13
Core: Deferoxamine (DFO). For Extension Labeled as DFO to DFO	3.32	5.25

Intervention	Percent (Mean)
	Change from Baseline at 6 Month (n= 85, 73)	Change from Baseline at 12 Month/EOS (n= 91, 81)
Core; Deferasirox (ICL). For Extension Labeled as ICL to ICL	1.81	1.79
Core: Deferoxamine (DFO). For Extension Labeled as DFO to DFO	1.48	1.10

Intervention	(umol/L) (Mean)
	Month 1, 0 hour (predose)	Month 1, 1 hour (post dos)	Month 1, 2 hour (post dose)	Month 1, 4 hour (post dose)	Month 2, 0 hour (predose)	Month 2, 1 hour (post dose)	Month 2, 2 hour (post dose)	Month 2, 4 hour (post dose)
Deferasirox (ICL). For Extension Labeled as ICL to ICL	32.25	96.32	136.47	133.33	38.66	119.48	177.19	180.76